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Posttraumatic Stress Disorder (PTSD) is an anxiety disorder that affects over 7.7 million
adults and carries an estimated societal cost of $3.1 billion every year. People develop PTSD
after exposure to a traumatic event. Alone or combined, approved pharmacotherapies or
psychotherapy are somewhat effective, but symptoms for many remain refractory. Emerging
evidence suggests that opiate systems may modulate the development and expression of PTSD,
and their role can be investigated preclinically. Pavlovian fear conditioning is a preclinical model
which elicits behaviors mirroring those that occur in humans during and after exposure to
trauma. This presents an experimental tool that can help elucidate the opiate mechanisms
involved in traumatic memory as well as the resulting fear behavior.

Mu opioid receptor (MOR) analgesics, such as morphine, are often given as a response to
trauma, and there is emerging evidence that they are, at least partially, protective against PTSD.
The kappa opioid receptor (KOR) system has also been implicated in stress-related processes,
with KOR agonists reported to enhance stress in both laboratory animals and in humans, and
KOR antagonists reported to attenuate stress-like behaviors preclinically. This project attempted
to clarify part of the role of the mu and kappa opiate receptor systems in mediating effects of
Pavlovian fear conditioning in mice as a predictor of their involvement in some of the signs and
symptoms of PTSD.
Kappa agonists increased acute fear responses but surprisingly also facilitated fear
extinction learning. This would suggest that the use of kappa agonists might increase the
efficiency and effectiveness of this therapy and could improve existing PTSD patient outcomes.
MOR agonists, as well as KOR antagonists reduced acute and long-term fear behavior. These
results support that the use KOR analgesics like morphine and fentanyl in the treatment of
trauma could have an added benefit of reducing the emergence and persistence of PTSD. Selfmedication may help explain the comorbidity of opioid abuse in PTSD patient populations.
Understanding the relative effects of these opiate ligands could lead to more informed usage of
MOR analgesics which vary in mu and kappa receptor activity under battlefield and other
traumatic conditions.

Introduction
Poppies and PTSD: Opioid influence on a preclinical model of posttraumatic stress disorder.
Posttraumatic stress disorder, its neurobiology and its current treatment.
Posttraumatic Stress Disorder (PTSD) currently affects over 7.7 million adults in the U.S.
and prevalence is increasing (Kessler et al., 2005; Kessler, Sonnega, Bromet, Hughes, & Nelson,
1995). PTSD treatment can involve psychotherapy and pharmacotherapy. The most effective
PTSD psychotherapy is exposure based behavioral therapy (Hetrick, Purcell, Garner, & Parslow,
2010). This method involves the exposure of the patient to aversive stimuli (real or simulated)
under controlled conditions. The two pharmacotherapies approved by the FDA to treat PTSD
(Paxil and Zoloft) are antidepressants. These drugs can reduce the general anxiety or comorbid
depression associated with PTSD but leave many symptoms untreated (Hetrick, et al., 2010).
Alone or combined, these two types of treatment are sometimes effective, but symptoms for
many remain refractory (Cooper, Carty, & Creamer, 2005; Hamner & Robert, 2005; Hetrick, et
al., 2010). This leaves not only room for improvement in treatment development but also, in the
study of the basic psychobiological mechanisms involved in PTSD.
It is important to understand how drugs influence the presentation and formation of
PTSD. Of specific interest are opioids. Several clinical studies show a relationship between
morphine administration and a reduction in PTSD risk (Nixon, Ellis, Nehmy, & Ball, 2010). In
one, the medical records of 696 injured U.S. military personnel without serious traumatic brain
injury were analyzed, in cases where morphine was administered during early resuscitation and
trauma care, 61% of patients developed PTSD as opposed to 76% of patients who did not receive
morphine (Holbrook, Galarneau, Dye, Quinn, & Dougherty, 2010). Results were similar in a
sample of 48 adolescents who were examined within 4 weeks of an injury that led to hospital
1

treatment. Morphine administration was associated with dose dependent reductions in PTSD
diagnosis at a 6 month follow-up assessment (Nixon et al., 2010). This result was repeated in a
different sample of 90 7-17 year olds assessed in an identical manner (Nixon, Nehmy, et al.,
2010; Stoddard et al., 2009) and in an additional sample of 120 trauma victims assessed at 3
months post event (Bryant, Creamer, O'Donnell, Silove, & McFarlane, 2009). These studies
show that there is a positive relationship between the dose of morphine administered and a
decrease in likelihood of developing PTSD. In sum, these results also show that this relationship
exists in humans of diverse ages and trauma sources. It is important therefore to investigate how
opioids affect the expression and formation of PTSD. One place to start that large undertaking is
to use a preclinical model of the disorder and investigate the effects of opioids on that model.

Posttraumatic Stress Disorder Criteria
Trauma associated anxiety has been discussed in medical literature earlier than the civil
war though not known as PTSD, but by colloquialisms like shell-shock, war neurosis and battle
fatigue (Newport & Nemeroff, 2000). It was not until the third edition of the APA’s Diagnostic
and Statistical Manual of Mental Disorders (DSM) in 1980 that trauma related anxiety
syndromes were recognized and named posttraumatic stress disorder (Newport & Nemeroff,
2000). This inclusion in the DSM was controversial. Many of the disorders symptoms
overlapped with anxiety and mood disorders and so both the placement and uniqueness of the
disorder was questioned (Horowitz, Weiss, & Marmar, 1987; Kinzie & Goetz, 1996). Since its
inclusion in the DSM the diagnosis has undergone refinement and we have gained more
knowledge about the unique psychobiology of PSTD that firmly cements the disorder as a
distinctive diagnosis (Kellner & Yehuda, 1999; Yehuda, 2000, 2001).

2

The current diagnostic criteria for PTSD specify it as a complex and lasting anxiety
response resulting from exposure to extreme trauma. PTSD presents with characteristic
symptoms including persistent re-experiencing of the traumatic event, persistent avoidance of
stimuli associated with the trauma and numbing of general responsiveness, and persistent
symptoms of increased arousal. The symptoms must be present for more than 1 month and the
disturbance must cause clinically significant distress or impairment in social, occupational, or
other important areas of functioning (DSM-IV™, 2000). A unique and essential feature of PTSD
is the development of these characteristic symptoms following exposure to an extreme traumatic
stressor. This stressor involves either direct personal experience of an event that involves death,
injury, or a threat to the physical integrity of the person,; or witnessing an event that involves
death, injury, or a threat to the physical integrity of another person,; or learning about unexpected
or violent death, serious harm, or threat of death or injury experienced by a family member or
other close associate (DSM-IV™, 2000). This criterion is unique in the presentation of
psychological disease in that it provides an external marked precipitating event in the
development of a psychiatric disorder (A criterion). The disorder may be especially severe or
long lasting when the stressor is of human design (e.g., torture, rape). The likelihood of
developing this disorder may increase as the intensity of and physical proximity to the stressor
increase (DSM-IV™, 2000). Other important criterion are divided into three categories: Reexperiencing the event or the physiological reactive state present in the original instance (B
criterion), avoidance of thoughts, feelings, actions or any stimuli that might remind them of or be
similar to the original instance (C criterion), as well as a change in the overall basal level of
anxiety and reactivity to stressful stimuli (D criterion) known as hyper-arousal (DSM-IV™,
2000).

3

The clinical B Criterion of re-experiencing the event can present in diverse ways.
Commonly the person has recurrent and intrusive recollections of the event (Criterion B1) or
recurrent distressing dreams during which the event is replayed (Criterion B2). In rare instances,
the person experiences dissociative states that last from a few seconds to several hours, or even
days, during which components of the event are relived and the person behaves as though
experiencing the event at that moment (Criterion B3). Intense psychological distress (Criterion
B4) or physiological reactivity (Criterion B5) often occurs when the person is exposed to
triggering events that resemble or symbolize an aspect of the traumatic event (e.g. anniversaries
of the traumatic event; hot humid weather for combat veterans of the South Pacific or hot dry
weather for veterans of Iraq and Afghanistan; entering any parking garage for a woman who was
raped in a parking garage) (DSM-IV™, 2000).
The person will make persistent attempts to limit exposure to stimuli associated with the
trauma. They will try to avoid thoughts, feelings, or conversations about the traumatic event
(Criterion C1) and to avoid activities, situation, or people who arouse recollections of it
(Criterion C2). This avoidance of reminders may include amnesia for an important aspect of the
traumatic event (Criterion C3). Diminished responsiveness to the external world, referred to as
"psychic numbing" or "emotional anesthesia," usually begins soon after the traumatic event. The
individual may complain of having markedly diminished interest or participation in previously
enjoyed activities (Criterion C4), of feeling detached or estranged from other people (Criterion
C5), or of having markedly reduced ability to feel emotions (especially those associated with
intimacy, tenderness, and sexuality) (Criterion C6). The individual may have a sense of a
foreshortened future (e.g., not expecting to have a career, marriage, children, or a normal life
span) (Criterion C7)(DSM-IV™, 2000).
4

These continual symptoms of anxiety or increased arousal experienced by the person
were not present before the trauma. These symptoms may include difficulty falling or staying
asleep that may be due to recurrent nightmares during which the traumatic event is relived
(Criterion D1), hypervigilance (Criterion D4), and exaggerated startle response (Criterion D5).
Some individuals report irritability or outbursts of anger (Criterion D2) or difficulty
concentrating or completing tasks (Criterion D3)(DSM-IV™, 2000).
The diagnosis can also include specifiers denoting onset and duration of symptoms. The
diagnosis includes the specifier Acute when the duration of symptoms is less than 3 months.
When symptoms last 3 months or longer then the diagnosis might include the specifier Chronic.
Finally the specifier Delayed Onset indicates that at least 6 months have passed between the
traumatic event and the onset of the symptoms (DSM-IV™, 2000). As with many psychiatric
diagnoses there is a very complex set of symptoms associated with PTSD. It is important as with
other disorders to attempt to understand the physiological processes involved in the initiation and
expression of PTSD.
Neurobiology of PTSD
The neurobiological changes which occur as a result of exposure to trauma or stress have
been studied with increasing interest since PTSD’s inclusion in the DSM. The changes in
neurobiology related to PTSD are complex, involving dysregulation of neurotransmitters such as
serotonin and norepinephrine, as well as the sympathetic nervous system (fight or flight) and
Hypothalamic-Pituitary-Adrenal (HPA) axis (Heim & Nemeroff, 2009). The bulk of
neurobiological PTSD research has concentrated on the HPA axis.
The Hypothalamic-Pituitary-Adrenal axis. The HPA axis is the major stress response
system and exerts its influence through the activation of adrenal glands through neuropeptide
release. Upon exposure to stress, neurons in the hypothalamic paraventricular nucleus secrete
5

corticotropin-releasing factor (CRF) from the median eminence into the hypothalamohypophyseal portal circulation, in which the peptide is transported to the anterior pituitary where
it stimulates the production and release of adrenocorticotropic hormone (ACTH).
Adrenocorticotropic hormone, in turn, stimulates the release of glucocorticoids from the adrenal
cortex. Glucocorticoids affect metabolism, immune function, and the brain, altering
physiological functions and behavior in reaction to the stressor. Multiple brain pathways
modulate HPA axis activity. The hippocampus and prefrontal cortex (PFC) inhibit the HPA axis,
whereas the amygdala and monoaminergic input from the brainstem stimulate the activity of
paraventricular nucleus CRF neurons (Heim & Nemeroff, 2009). Glucocorticoids exert negative
feedback control of the HPA axis by regulating hippocampal and hypothalamic paraventricular
nucleus neurons, as well as ACTH secretion, through binding to glucocorticoid receptors (GR).
Sustained glucocorticoid exposure has adverse effects on hippocampal neurons, including
reduction in dendritic branching, and loss of dendritic spines (Arborelius, Owens, Plotsky, &
Nemeroff, 1999; Fuchs & Gould, 2000; Nestler et al., 2002).
Exposure to acute stressors activates the HPA axis this should result in an increased level
of cortisol (a glucocorticoid released after exposure to stress), but paradoxically studies in
combat veterans with PTSD revealed low concentrations of cortisol measured in urine or blood,
compared to healthy controls (Yehuda, 2006; Yehuda et al., 1990). This counterintuitive finding
has been replicated in Holocaust survivors, refugees, and abused persons with PTSD, although
findings are not uniformly consistent across studies (Yehuda, 2006; Yehuda, et al., 1990). Other
studies have shown similar to normal or even elevated levels of cortisol, differences in type and
timing of the psychological trauma, symptom patterns, comorbidity, personality, and genetic
dispositions, among other factors, may contribute to this inconsistency (Meewisse, Reitsma, de
Vries, Gersons, & Olff, 2007). Studies using low-dose dexamethasone suppression and
6

metyrapone testing, two pharmacologic agents that alter the availability of stress hormones
exerting feedback on the HPA axis, revealed that hypocortisolism in PTSD occurs in the context
of increased sensitivity of the HPA axis to negative glucocorticoid feedback (Yehuda, 2006;
Yehuda, Yang, Buchsbaum, & Golier, 2006). Findings of increased GR binding and function
support the assumption of increased negative feedback sensitivity of the HPA axis in PTSD
(Yehuda, 2006). At the central nervous system (CNS) level, increased cerebrospinal fluid
concentrations of CRF have been measured in patients with PTSD, both in single lumbar
puncture and serial sampling studies (Baker et al., 1999; Bremner, Licinio, et al.,
1997). Sustained elevations in CRF concentrations were observed despite comparably low
cortisol concentrations, and the latter were negatively correlated with PTSD symptoms (Baker, et
al., 1999). There is evidence of blunted adrenocorticotropic hormone response to intravenous
cortisol stimulation in PTSD patients (Yehuda, 2006). The below normal levels of
adrenocorticotropic hormone in response to exogenous cortisol in PTSD patients when compared
to healthy volunteers suggests that the glucocorticoid system is less active in PTSD patients
possibly due to a reduction in the total response levels of the system. One mechanism that may
explain this is the downregulation of CRF receptors as a compensatory response to elevated
cortisol levels seen in early diagnosed PTSD patients (Yehuda, 2006). In addition, reduced
volume of the hippocampus, the major brain region inhibiting the HPA axis, is a cardinal feature
of PTSD (Bremner, Elzinga, Schmahl, & Vermetten, 2008). Taken together, the specific
constellation of neuroendocrine findings in PTSD reflects sensitization of the HPA axis to
exposure to stressors. This neuroendocrine pattern distinguishes PTSD from major depression, a
frequently comorbid but distinct disorder (Yehuda, 2006).
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Interestingly, prospective studies have shown that low cortisol levels at the time of
exposure to psychological trauma predict the development of PTSD (Resnick, Yehuda, Pitman,
& Foy, 1995; Yehuda, McFarlane, & Shalev, 1998), suggesting that hypocortisolism might be a
preexisting risk factor that is associated with maladaptive stress responses such as PTSD.
Consequently, administration of hydrocortisone directly after exposure to psychological trauma
has been shown to reduce the risk for later development of PTSD in humans in several studies
(de Quervain, 2008; Schelling et al., 2004). In addition, it was recently demonstrated that
hydrocortisone treatment, simulating normal circadian cortisol rhythm, is effective in reducing
some symptoms PTSD (Aerni et al., 2004). Indeed, decreased availability of cortisol, and hence
lack of regulatory effects in the CNS, may have permissive effects towards the sustained
activation of neural systems involved in stress reactivity and fear processing, including the CRF
and norepinephrine (NE) systems (Heim, Ehlert, & Hellhammer, 2000; Yehuda,
2006). Glucocorticoids further interfere with the retrieval of traumatic memories and thereby
may prevent or reduce symptoms of PTSD (de Quervain, 2008; de Quervain & Margraf, 2008).
Hypothalamic-Pituitary-Thyroid Axis. The HPT axis is an additional response to stress
that has only more recently been studied in relation to PTSD. When the HPT axis is activated
thyrotropin-releasing hormone (TRH) is released from the hypothalamus which stimulates the
secretion of thyrotropin stimulating hormone (TSH) from the anterior pituitary gland. TSH, in
turn, stimulates the thyroid gland to secrete thyroxine (T4) and tri-iodothyronine (T3).
The thyroid axis is capable of emergency responses and increased T4 levels are part of an arousal
signal (Mason, 1968). Increased HPT axis activity has been observed in PTSD patients as well as
a link between hyperthyroidism and traumatic stress (Prange, 1999). Specifically the peripheral
measures of the total and free fractions of T3 and T4 are elevated in patients with PTSD (Newport
8

& Nemeroff, 2000). The relative increases of T3 and T4 are disproportionate with a significantly
higher increase occurring in T3 levels than T4 levels. This suggests an increase in the peripheral
de-iodination of T4 to the more biologically active T3. This supports the observation of a
sensitized response of the HPT system in PTSD patients. Which is further maintained by the
elevated TSH release that occurs in PTSD patients when TRH is administered under testing
conditions (Prange, 1999).
Hippocampus. The most reproducible finding in structural imaging studies of PTSD is
reduced volume of the hippocampus. The hippocampus is implicated in the control of stress
responses, declarative memory and contextual aspects of fear conditioning, and is known as one
of the most plastic regions in the brain. As noted above, prolonged exposure to stress and high
glucocorticoid levels damages the hippocampus, leading to reduction in dendritic branching, loss
of dendritic spines, and impairment of neurogenesis (Fuchs & Gould, 2000). Initial magnetic
resonance imaging studies demonstrated smaller hippocampal volumes in Vietnam veterans with
PTSD and patients with abuse-related PTSD compared to controls (Bremner et al., 1995;
Bremner, Randall, et al., 1997; Gurvits et al., 1996; Stein, Koverola, Hanna, Torchia, &
McClarty, 1997). Small hippocampal volumes were associated with the severity of trauma and
memory impairments in these studies. These findings were generally replicated in subsequent
studies. Studies using proton magnetic resonance spectroscopy (MRS) observed reduced levels
of N-acetyl aspartate (NAA), a marker of neuronal integrity, in the hippocampus of adult patients
with PTSD (Rauch, Shin, & Phelps, 2006). Of note, NAA reductions were correlated with serum
cortisol concentrations (Neylan et al., 2003). Interestingly, reduced hippocampal volume was not
observed in children with PTSD (De Bellis et al., 1999). Hippocampal volume reduction in
PTSD may reflect toxic effects over time of repeatedly increased glucocorticoid exposure or
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increased glucocorticoid sensitivity, though recent evidence also suggests that a small
hippocampus might represent a preexisting vulnerability factor for developing PTSD (Pitman et
al., 2006). Moreover, in patients with major depression an early life trauma in the form of
childhood abuse is associated with reduced hippocampal volume (Vythilingam et al.,
2002). Indeed, hippocampal deficits may promote activation of and failure to shut down stress
responses, and may contribute to impaired extinction of conditioned fear as well as deficits in
discriminating between safe and unsafe contexts. Studies using functional neuroimaging have
further revealed that PTSD patients exhibit deficits in hippocampal activation during a verbal
declarative memory task (Bremner et al., 1999). Both hippocampal atrophy and functional
deficits reverse after successful treatment with selective serotonin reuptake inhibitors (commonly
used to treat depression) (Bremner & Vermetten, 2004), which have been demonstrated to
increase neurotrophic factors and neurogenesis in preclinical studies (Nestler, et al., 2002).
Amygdala. In addition to the hippocampus, other brain structures implicated in a neural
circuitry of stress include the amygdala and the prefrontal cortex. The amygdala is a critical
limbic structure involved in emotional processing and in the acquisition of fear responses. The
amygdala is connected to both cortical and subcortical regions. The basolateral complex is
innervated by neocortical and subcortical sensory regions and sends information to the central
nucleus of the amygdala. The central nucleus projects to the midbrain and brainstem nuclei to
coordinate rapid autonomic, endocrine, and behavioral responses to danger. The central nucleus
also receives visceral information from brainstem regions. Connections between the amygdala
and the hippocampus are implicated in context conditioning. Connections between the PFC and
the amygdala modulate stress responsiveness and mediate extinction of fear memory, inasmuch
as the PFC exerts inhibitory control over the amygdala (Schulkin, 2006). The functional role of
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the amygdala in mediating both stress responses and emotional learning suggests that changes in
this region and its connected circuitry may be implicated in the pathophysiology of PTSD.
Although there is no clear evidence for structural alterations of the amygdala in PTSD,
functional imaging studies have revealed hyperresponsivity of the amygdala in PTSD during the
presentation of traumatic scripts, cues, and other reminders (Liberzon & Sripada, 2008; Shin,
Rauch, & Pitman, 2006). PTSD patients further show increased amygdala responses to general
emotional stimuli that are not associated with the trauma, such as emotional faces(Shin, et al.,
2006). Of note, the amygdala also seems to be sensitized to subliminally presented threatening
cues in PTSD (Hendler et al., 2003; Rauch et al., 2000; Schulkin, 2006). Increased amygdala
activation has also been reported for PTSD patients during fear acquisition in a conditioning
experiment (Bremner et al., 2005). Given that increased amygdala reactivity has been linked to
genetic traits (Hariri et al., 2002), which moderate risk for PTSD (Kilpatrick et al.,
2007), increased amygdala reactivity may represent a biological risk factor for the development
of PTSD.
Prefrontal Cortex. The medial prefrontal cortex (mPFC) comprises the anterior
cingulate cortex (ACC), subcallosal cortex, and the medial frontal gyrus. The mPFC is connected
with the amygdala, where it exerts inhibitory control over stress responses and emotional
reactivity. The mPFC further mediates extinction of conditioned fear through active inhibition of
acquired fear responses (Shin, et al., 2006). Patients with PTSD exhibit decreased volumes of the
frontal cortex (Rauch et al., 2003), including reduced volumes of the ACC (Woodward et al.,
2006; Yamasue et al., 2003). The reduction in ACC volume was correlated with PTSD symptom
severity in some of these studies. Altered shape of the ACC (Corbo, Clement, Armony,
Pruessner, & Brunet, 2005) and decreased NAA concentrations in the ACC (De Bellis,
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Keshavan, Spencer, & Hall, 2000) have also been reported in PTSD patients. A recent twin study
suggests that volume loss in the ACC is an acquired correlate of having PTSD, rather than a
preexisting risk factor (Kasai et al., 2008). Functional imaging studies have found decreased
activation of the mPFC in PTSD patients in response to stimuli, such as traumatic scripts
(Britton, Phan, Taylor, Fig, & Liberzon, 2005; Shin et al., 2004), combat pictures and sounds
(Bremner, et al., 1999), trauma unrelated negative narratives (Lanius et al., 2003), fearful faces
(Shin et al., 2005), emotional Stroop(Bremner et al., 2004), and others, though there are also
discordant findings (Shin, et al., 2006). Reduced activation of the mPFC was associated with
PTSD symptom severity in several of these studies and successful selective serotonin re-uptake
inhibitor (SSRI) treatment restored mPFC activation patterns(Shin, et al., 2006). Of note, in the
above cited conditioning experiment (Bremner, et al., 2005), extinction of conditioned fear was
associated with decreased activation of the ACC, providing a biological basis for imprinted
traumatic memories in PTSD. Given the connectivity between the amygdala and mPFC,
interactions in activation patterns between these regions have been reported in PTSD, though the
direction of the relationship is inconsistent across studies (Shin, et al., 2006).
Catecholamines. The catecholamines comprise a family of neurotransmitters derived
from the amino acid tyrosine. The rate-limiting factor in the synthesis of catecholamines is
tyrosine hydroxylase, an enzyme that converts tyrosine into DOPA, which subsequently is
converted into dopamine (DA) by the action of DOPA decarboxylase. In noradrenergic neurons,
dopamine β hydroxylase converts DA into NE. NE is one of the principal mediators of the CNS
and autonomic stress responses. The majority of CNS NE is derived from neurons of the locus
ceruleus (LC) that project to various brain regions involved in the stress response, including the
PFC, amygdala, hippocampus, hypothalamus, periaqueductal grey, and thalamus. There is
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evidence for a feed-forward circuit connecting the amygdala and the hypothalamus with the LC,
in which CRF and NE interact to increase fear conditioning and encoding of emotional
memories, enhance arousal and vigilance, and integrate endocrine and autonomic responses to
stress. Glucocorticoids inhibit this cascade (Pavcovich & Valentino, 1997). In the periphery,
sympathoadrenal activation during exposure to stressors results in the release of NE and
epinephrine from the adrenal medulla, increased release of NE from sympathetic nerve endings,
and changes in blood flow to a variety of organs, reflecting an alarm reaction that mobilizes the
body to allow for optimal coping. The effects of NE are mediated via postsynaptic α1, β1 and
β2 receptors, whereas another NE-activated receptor, the α2 receptor, serves as a presynaptic
autoreceptor inhibiting NE release (Koob, 1999). Because of its multiple roles in regulating
arousal and autonomic stress responses, as well as promoting the encoding of emotional
memories, NE has been a central candidate in studying the pathophysiology of PTSD.
A cardinal feature of patients with PTSD is sustained hyperactivity of the sympathetic
branch of the autonomic nervous system, as evidenced by heart rate, blood pressure, skin
conductance level, and other psychophysiological measures. Accordingly, increased urinary
excretion of NE and epinephrine, and their metabolites, has been documented in combat
veterans, abused women, and children with PTSD. In addition, patients with PTSD exhibit
increased heart rate, blood pressure, and NE responses to challenge, such as traumatic reminders.
Decreased platelet α2 receptor binding further suggests NE hyperactivity in PTSD (Strawn &
Geracioti, 2008; Vermetten & Bremner, 2002). There is also evidence for a role of altered CNS
NE function in PTSD. Administration of the α2 receptor antagonist yohimbine, which increases
NE release, induces symptoms of flashbacks and increased autonomic responses in patients with
PTSD (Southwick et al., 1999). Serial sampling revealed sustained increases in CSF NE
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concentrations and increased CSF NE responses to psychological stressors in PTSD (Geracioti et
al., 2001; Geracioti et al., 2008). Taken together, increased CNS NE activity plausibly
contributes to features of PTSD, including hyperarousal, increased startle, and encoded fear
memories(Strawn & Geracioti, 2008).
Interestingly, prospective studies have shown that increased heart rate and peripheral
epinephrine excretion at the time of exposure to trauma predict subsequent development of
PTSD (Delahanty & Nugent, 2006; Yehuda, et al., 1998). Remarkably, administration of the
centrally acting β adrenergic blocker propranolol shortly after exposure to psychological trauma
has been reported to reduce PTSD symptom severity and reactivity to reminders of the traumatic
event (Pitman et al., 2002). Although this did not prevent the development of PTSD, it may have
blocked traumatic memory consolidation (Brunet et al., 2008), and therefore may reduce the
severity or chronicity of PTSD. Various anti-adrenergic agents have been tested for their
therapeutic efficiency in the treatment of PTSD in open label trials, though there is a paucity of
controlled trials (Strawn & Geracioti, 2008).
It should be noted that increased urinary excretion of DA and its metabolite has been
reported for patients with PTSD. At the CNS level, mesolimbic DA plays a critical role in the
processing of rewards. DA has also been implicated in fear conditioning. There is evidence in
humans that exposure to stressors induces mesolimbic DA release, which in turn may impact on
HPA axis responses. Whether or not the CNS DA system is altered in PTSD remains unclear,
though genetic variations in the DA system have been implicated in moderating risk for PTSD.
Serotonin. Serotonin, also known as 5-hydroxytryptamine (5-HT), is a monoamine
neurotransmitter synthesized from the amino acid tryptophan. Serotonergic neurons originate in
the dorsal and medial nuclei raphé in the brainstem and project to multiple forebrain regions,
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including the amygdala, bed nucleus of the stria terminalis, hippocampus, and PFC. This
indoleamine has roles in regulating sleep, appetite, sexual behavior, aggression/impulsivity,
motor function, analgesia, and neuroendocrine control. It also has been implicated in the
pathophysiology of mood and anxiety disorders and in the modulation of affective and stress
responses. The direction of the modulatory effects of 5-HT on affective and stress responses
depends on stressor intensity, brain region, and receptor type. It is believed that 5-HT neurons of
the dorsal raphé projecting to the amygdala and hippocampus mediate anxiogenic (stressincreasing) effects via 5-HT2receptors, whereas 5-HT neurons from the median raphé exert
anxiolytic effects, facilitate extinction, and suppress encoding of learned associations via 5HT1A receptors. Chronic exposure to stressors induces upregulation of 5-HT2 and downregulation
of 5-HT1A receptors, respectively, in animal models. 5-HT1A receptor knockout mice exhibit
increased stress responses. The 5-HT system interacts with the CRF and NE systems in
coordinating affective and stress responses (Ressler & Nemeroff, 2000; Vermetten & Bremner,
2002). Indirect evidence suggests a role of 5-HT in the pathophysiology of PTSD, including
symptoms of impulsivity, hostility, aggression, depression, and suicidality. Most important
concerning a role of 5-HT circuits in PTSD is the demonstrated partial efficacy of the SSRIs as
treatments. However, though their use is indeed recommended in many current treatment
guidelines the Institute of Medicine concluded that there is insufficient evidence for the efficacy
of the approved medications for PTSD, Sertraline and Paroxetine (Institute of Medicine (U.S.).
Committee on Treatment of Posttraumatic Stress Disorder., 2008).
Other evidence for altered 5-HT neurotransmission in PTSD includes decreased serum
concentrations of 5-HT, decreased density of platelet 5-HT uptake sites, and altered
responsiveness to CNS serotonergic challenge (Ressler & Nemeroff, 2000; Vermetten &
Bremner, 2002). However, no differences in CNS 5-HT1A receptor binding were detected in
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patients with PTSD compared to controls using positron emission tomography (PET) imaging
(Bonne et al., 2005). Taken together, altered 5-HT transmission may contribute to symptoms of
PTSD such as hypervigilance, increased startle, impulsivity, and intrusive memories.
GABA/Benzodiazepine Receptor System. Gamma-aminobutyric acid (GABA) is the
principal inhibitory neurotransmitter in the CNS. GABA exerts anxiolytic effects and dampens
behavioral and physiological responses to stressors, in part by inhibiting the CRF/NE circuits
involved in mediating fear and stress responses. GABA acts on GABAA receptors, part of the
GABAA/benzodiazepine (BZ) receptor complex. Uncontrollable stress has been shown to lead to
alterations in the GABAA/BZ receptor complex. Treatment with BZ, GABA agonists, or GABA
reuptake inhibitors decreases symptoms of anxiety in PTSD, suggesting that the GABA/BZ
system may be involved in the pathophysiology of PTSD. Patients with PTSD exhibit decreased
platelet BZ binding sites (Gavish et al., 1996). Single photon emission computed tomography
and PET imaging studies revealed decreased BZ receptor binding in the cortex, hippocampus and
thalamus of patients with PTSD. These results suggest that decreased density or affinity of the
BZ receptor may play a role in PTSD (Bremner et al., 2000; Geuze et al., 2008). However,
treatment with BZs after exposure to psychological trauma does not prevent PTSD (Gelpin,
Bonne, Peri, Brandes, & Shalev, 1996). Although there are multiple studies implicating the
GABA/BZ receptor system in anxiety disorders, studies in PTSD are relatively sparse (Strawn &
Geracioti, 2008).
Glutamate/NMDA Receptor System. Glutamate is the primary excitatory
neurotransmitter in the CNS. Exposure to stressors and the release or administration of
glucocorticoids increases glutamate release in the brain. Glutamate binds to several so-called
excitatory amino acid receptors, one of which is the N-methyl-D-aspartate (NMDA) receptor.
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The glutamate/NMDA receptor system has been implicated in synaptic plasticity, learning, and
memory, including the well studied phenomenon of long term potentiation (LTP), the extended
excitation of neural circuits, leading to long-lasting enhancement in communication between
neurons. This process is believed in part to underlie the process of conditioning and memory
consolidation. LTP plausibly contributes to consolidation of trauma memories in PTSD. Of note,
the partial NMDA-receptor antagonist D-cycloserine has been shown to improve the extinction
of fear in rodents and in phobic patients undergoing exposure therapy. D-cycloserine has been
shown in many studies to enhance learning of many types including extinction learning (Choi,
Rothbaum, Gerardi, & Ressler, 2010; Kaplan & Moore, 2011). Whether or not D-cycloserine is
effective in enhancing the outcome of exposure therapy in PTSD remains to be studied (Davis,
Ressler, Rothbaum, & Richardson, 2006). In addition to its role in learning and memory,
overexposure to glutamate is associated with excitotoxicity, and plausibly could contribute to a
loss of neurons in the hippocampus and PFC in PTSD. Of note, elevated glucocorticoids increase
the expression and/or sensitivity of NMDA receptors, which may sensitize the brain to
excitotoxic insults.
Neuropeptide Y. Neuropeptide Y (NPY) is a neuropeptide with anxiolytic and stressbuffering properties. NPY has been shown to inhibit CRF/NE circuits involved in stress and fear
responses and reduces the release of NE from sympathetic nerve cells. A relative lack of NPY
may promote maladaptive stress responses and contribute to the development of PTSD. Indeed,
patients with PTSD have been reported to exhibit decreased plasma NPY concentrations and
blunted NPY responses to yohimbine challenge compared to controls, suggesting that decreased
NPY activity may contribute to noradrenergic hyperactivity in PTSD (Rasmusson et al.,
2000). However, it has been suggested that NPY may be involved in promoting recovery from or
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resilience to PTSD because combat veterans without PTSD have been demonstrated to exhibit
elevated plasma NPY levels compared to veterans with PTSD (Yehuda, Brand, & Yang, 2006).
Opioids. Endogenous opioids, such as the endorphins, enkephalins and dynorphins are
endogenous neuropeptides that act upon opiate receptors (which can also be activated by
synthetic or naturally occurring opiates like morphine or heroin). Endorphins work as an agonist
at and have a high affinity for mu receptors but also act at and have a slightly lower affinity for
kappa receptors. β-Endorphin is a cleavage product of pro-opiomelanocortin (POMC), which is
also the precursor hormone for adrenocorticotropic hormone. Dynorphins act primarily through
the kappa receptor but can have some activity through mu receptors. Enkephalins are divided in
to leu-enkephalin which work through delta type opioid receptors and met-enkephalin which
works through mu and delta receptors. Alterations in endogenous opioids have been postulated to
be involved in symptoms of numbing, stress-induced analgesia, and dissociation in PTSD (Heim
& Nemeroff, 2009). Endogenous opioids further exert inhibitory influences on the HPA axis as
evidenced by attenuated stress induced release of NE in the thalamus, hypothalamus,
hippocampus, amygdala and midbrain when rats were pre-treated with morphine (Tanaka et al.,
1983). Opiate effects may occur through a reduction in the firing of the LC and may explain
heroin’s alleviation of the hyperarousal symptoms of some PTSD patients (Bremner, Southwick,
Darnell, & Charney, 1996). Heroin addicted individuals in comparison with healthy volunteers
have been shown to exhibit significantly lower levels of adrenocorticotropic hormone, as well as
have reduced levels HPA axis activation in response to a stressor (Gerra et al., 2004; Ho et al.,
1977). Naloxone, an opiate receptor antagonist, increases HPA axis activity by blocking an
inhibitory opioidergic influence on hypothalamic CRF secretion, and patients with PTSD have
been reported to exhibit an exaggerated HPA axis response to naloxone. Interestingly, naloxone
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also has been shown to reverse the analgesia of PTSD patients after exposure to traumatic
reminders. Also, PTSD patients exhibit increased CSF β-endorphin levels, suggesting increased
activation of the endogenous opioid system. Interestingly, the opiate receptor antagonist,
naltrexone, has been reported to be effective in treating symptoms of dissociation and flashbacks
in traumatized patients (Newport & Nemeroff, 2000; Strawn & Geracioti, 2008). Finally
administration of morphine has been linked to a reduction in risk of the development of PTSD
(Bryant, et al., 2009; Holbrook, et al., 2010; Nixon, Nehmy, et al., 2010; Stoddard, et al., 2009).
Several clinical studies show a relationship between morphine administration and a
reduction in PTSD risk (Nixon, Ellis, et al., 2010). In one, the medical records of 696 injured
U.S. military personnel without serious traumatic brain injury were analyzed, in cases where
morphine was administered during early resuscitation and trauma care, 61% of patients
developed PTSD as opposed to 76% of patients who did not receive morphine(Holbrook, et al.,
2010).. Results were similar in a sample of 48 adolescents who were examined within 4 weeks of
an injury that led to hospital treatment. Morphine administration was associated with dose
dependent reductions in PTSD diagnosis at a 6 month follow-up assessment (Nixon, Nehmy, et
al., 2010). This result was repeated in a different sample of 90 7-17 year olds assessed in an
identical manner (Nixon, Nehmy, et al., 2010; Stoddard, et al., 2009) and in an additional sample
of 120 trauma victims assessed at 3 months post event (Bryant, et al., 2009). These studies
show that there is a positive relationship between the dose of morphine administered and a
decrease in likelihood of developing PTSD. In sum, these results also show that this relationship
exists in humans of diverse ages and trauma sources. There are at least three possible
mechanisms by which opioids may protect against PTSD; reducing pain, preventing memory
consolidation, and modulation of HPA axis activity.
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Opioids exert pain relief through the activation of specific membrane receptors. There are
three major subtypes of receptors, mu, kappa, and delta, which are located in diverse areas of the
central nervous system (Kanjhan, 1995). The brain contains multiple endogenous opioid
peptides: enkephalins, dynorphins, and endorphins. These peptides are released into the brain
and blood following stress or pain (Akil et al., 1984). Both endogenous opioid peptides
mentioned above and exogenous opioid peptides (produced outside the body either botanically or
chemically) can relieve pain. Some literature suggests that pain relief may be the primary
mechanism by which morphine may reduce PTSD risk. The relief of pain may make the trauma
less stressful (Stoddard, et al., 2009).
Opioids have been repeatedly shown to affect and regulate memory. This is accomplished
physiologically by beta-endorphin’s release after exposure to a novel situation. This state
dependent effect is reversible by mu antagonists like naloxone. This occurs in several brain areas
including the amygdala. In addition to this state dependant effect, administration of mu opioid
agonists reduces memory retention, which may be due to an amnesiac effect (Izquierdo et al.,
1980).For example, in healthy human volunteers subtle working memory impairments were
found in women following both oxycodone and morphine administration (Friswell et al., 2008).
In a preclinical model, a pre-training single administration of morphine has been observed to
decrease the spatial memory acquisition in Morris water maze task in rats (Farahmandfar,
Karimian, Naghdi, Zarrindast, & Kadivar, 2010). Therefore, morphine may have memory effects
that prevent conditioning of traumatic stimuli.
The kappa opioid receptor (KOR) system has also been highly characterized with regards
to stress. The data supports that the kappa system influences and can be influenced by stress. A
variety of studies and reviews support endogenous opioid peptide systems involvement in the
mediation, modulation, and regulation of stress responses. Specifically the kappa opioid receptor
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subtype has been characterized regarding its role in stress (Bruchas, Land, & Chavkin, 2010).
The widespread distribution of enkephalin throughout the limbic system is consistent with the
kappa receptor system playing a direct role in the modulation of the stress response (Drolet et al.,
2001). Kappa opioid receptor antagonists have been found to block the aversive behaviors
brought on by forced swim (Beardsley, Howard, Shelton, & Carroll, 2005) and inescapable
footshock stress (Land et al., 2008). Opioid analgesics, though mostly active at mu receptor
subtypes, often act at other receptor subtypes like kappa. Thus it is important to investigate
kappa compounds as well as analgesics like morphine to help us understand if opioid stress
interactions are a part of morphine’s protective effect.
Psychological Approaches to the Treatment of PTSD
There are a large variety of psychological approaches to treating PTSD that may be used
singly or in conjunction. The most widely used of these treatments are based on the concepts
and traditions of cognitive behavioral therapy (Sharpless & Barber, 2011). Pharmacotherapy
approaches mentioned previously are often explored in addition to these psychological therapies.
Prolonged exposure. The foundations of prolonged exposure are closely related to
extinction learning and are intended to modify the memory processes first changed in the
traumatic exposure. The treatment usually consists of 8-15 weekly 90-minute sessions. There are
three main components; visualization and examination of traumatic memories, discussion and
examination of these memories along with in vivo exposure to trauma related stimuli and
situations in a safe controlled environment (Sharpless & Barber, 2011). The prolonged exposure
treatment method has the most data supporting its treatment efficacy as well as being one of two
treatments currently used by the Veterans Administration (VA) (Powers, Halpern, Ferenschak,
Gillihan, & Foa, 2010). Exposure therapy can also be modeled in preclinical assays and is more
21

effective when given in close temporal proximity to the initiating event. Mice, which were given
extinction therapy 24h after and one month after Pavlovian conditioning, had reduced freezing
behavior relative to controls, but only those given therapy at the 24h after time point showed a
reduction in hyperarousal symptoms (Golub, Mauch, Dahlhoff, & Wotjak, 2009).
Cognitive processing therapy. Though some components of cognitive processing
therapy have similarities to cognitive behavioral therapy as well as prolonged exposure the
treatment focuses on self-blame (Resick & Schnicke, 1992). The exposure component of
cognitive processing therapy is written rather than mental imagery. Specifically, clients are
instructed to write about their traumatic events in detail, review them daily and share them aloud
during sessions. The clients are assisted in labeling feelings and working through “stuck points”
in the narratives. The focus of this review is to process individual components of the experience
and how each makes them feel and think about the events (Sharpless & Barber, 2011). Cognitive
processing therapy has very good data supporting its use in PTSD (Forbes et al., 2012), and it
was chosen as the other psychological treatment to be extensively “rolled out” through the VA
system.
Eye movement desensitization and reprocessing .This treatment combines elements of
cognitive behavioral therapy, mindfulness, body-based approaches, and person-centered
therapies. It is clinically guided by the Adaptive Information Processing Model (Shapiro &
Maxfield, 2002) that proposes that traumatic memories in PTSD are unprocessed and are not
stored as memories, but are treated as if they were new sensory inputs. There are eight phases of
treatment in eye movement desensitization and reprocessing, of which the most unique are
termed desensitization and reprocessing (when clients hold distressing images in mind while
tracking rhythmic finger movements of the clinician), the installation of positive cognitions
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(during which fingers are tracked while holding positive cognitions in mind), and journaling
(Shapiro & Maxfield, 2002).
Stress inoculation training. Initially developed to manage anxious symptoms the group
of techniques known as stress inoculation training (relaxation, thought stopping, in vivo
exposure to feared situations) has been subsequently adapted to PTSD and other specific
disorders (E. B. Foa, Rothbaum, Riggs, & Murdock, 1991). Stress inoculation training has been
shown to be moderately effective in reducing PTSD symptoms, though eye movement
desensitization and reprocessing is slightly more effective (Lee, Gavriel, Drummond, Richards,
& Greenwald, 2002). More study should be done to discover which components are key to its
success due to inconsistent data (Edna B. Foa & International Society for Traumatic Stress
Studies., 2009).
Exposure therapy using virtual reality .With the advancements in technology we now
have the ability to use virtual exposure to stimuli instead of imagined or in vivo. Exposure
therapy using virtual reality may include convincing visual stimuli, 3D sound, smells, and a
general feeling of immersion in traumatic situations (Rothbaum, Rizzo, & Difede, 2010). This
treatment has been used with Iraq veterans in 19 military centers, and has seen some modest
success, especially with veterans who have difficulty with visualizing trauma or talk therapy
(Rothbaum, et al., 2010).
Relaxation training. Relaxation training may have been the earliest behavioral treatment
used for PTSD, and consists of using various techniques (e.g., successive tension and relaxation
of muscles) in order to reduce the fear and anxiety associated with traumatic responses. It has
been used as a standalone treatment (often as a control) and as a component of broader PTSD
treatments. Relaxation training has been used in four randomized clinical trials, and while
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certainly effective, it is not as effective as more comprehensive treatment packages (Sharpless &
Barber, 2011).
Cognitive behavioral group therapy. This treatment is as its name suggests cognitive
behavioral therapy in a group setting. While this treatment approach has been shown to be
effective, it has not been shown to be significantly better than other nonspecific treatment control
groups (Schnurr et al., 2003).
In summary, of the psychological therapies described here (i.e., those which have
undergone the most empirical testing), prolonged exposure, cognitive processing theory, and eye
movement and desensitization and reprocessing possess the most evidence in favor of their
efficacy and utility with veterans (Sharpless & Barber, 2011). However, these therapies are not
effective in many cases and many patients are still refractory (Hetrick, et al., 2010). As
described previously pharmacotherapies are also not effective in a large number of cases. This
leaves considerable room for improvement in treatment development. It is important to
understand how different drug treatments like opiates affect fear behavior so that better
treatments or combination therapy approaches can be developed.
Preclinical Models of PTSD
While the complexity of psychiatric disorders like PTSD cannot be fully replicated in a
preclinical assay, there are many existing preclinical assays that can be used to model key parts
of the disease. Some of these preclinical models observe and record well explored behaviors in
animals and how those behaviors might change in relation to stress. Other preclinical PTSD
models are newer adaptations of existing assays like fear potentiated startle, which combines an
associative learning component with a startle reflex two components now understood to be a
part of PTSD’s disease mechanism. There are different approaches to creating a preclinical
PTSD model (i.e. stress/trauma initiated, mechanism based, neurobiological system and genetic
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based)(Shiromani, LeDoux, & Keane, 2009). There are benefits and limitations on each
approach, it is important to understand the approaches and how they impact the conclusions that
can be drawn from the resulting data.
Neurobiological systems models of PTSD. Neurobiological models seek to initiate
biological systems changes (including the HPA axis) that mimic those that occur in PTSD
patients. Changes in neuroendocrine function and arousal that are characteristic of PTSD can be
induced by single prolonged stress exposure in rats. Decreased neural activity in the prefrontal
cortex, increased neural activity in the amygdala complex, and reduced neuronal integrity in
the hippocampus is associated with PTSD (Knox, Perrine, George, Galloway, & Liberzon,
2010). The single prolonged stress exposure models recreate to some extent these aspects of
PTSD.
Genetic model approaches to PTSD. The availability of the fully sequenced mouse
genome and the tools to manipulate that genome (gene knock-out, transgenic and gene silencing)
give us great tools to approach genetic influences in many disease states. The difficulty with
PTSD and many other psychiatric disorders is that there is no single gene or small group of
genes wholly responsible for the disorder. The picture that seems to be arising both from clinical
and preclinical studies is that there are genes which give rise to a certain predisposition for
developing a disorder given the addition of a certain environmental events. As described above,
there are many systems involved in the body’s complex stress response. Therefore, many genetic
and likely epigenetic factors are involved in the vulnerability for developing PTSD. At this point
in time, distinct genetic models do not exist for PTSD (Schmidt, Holsboer, & Rein, 2011).
Trauma/Stress initiated models of PTSD. Trauma/Stress initiated models of PTSD.
These assays seek to employ an initiating stress or trauma to represent the criterion A (direct
personal experience of an event that involves death, injury, or a threat to the physical integrity)
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of PTSD. This approach can include a physical stressor or a psychosocial stressor like predator
exposure. In addition, ethologically relevant stressors, such as predator exposure, produce lasting
increases in stress-related behavior and levels of corticosterone in plasma. Reports also
indicate habituation is less likely to occur with repeated exposure to a predator than with
repeated exposure to different stressors such as restraint (Plata-Salaman et al., 2000). While these
models are functional and provide data at the behavioral level, many do not shed light on
underlying brain mechanisms that are responsible for producing this behavior.
Mechanism based models of PTSD. The trauma or stress initiated models do a good job
of modeling short term stress behavior, but do not translate completely to the persistence and
resistance of symptoms present in the disorder. The fear conditioning paradigm mirrors the
learning and memory processes that occur in humans during traumatic exposure and displays
many signs that can be directly correlated to those seen in PTSD (E. B. Foa & Kozak, 1986;
Maren, 2001). In the mouse, Pavlovian fear conditioning (PFC) is observed by the animal
freezing in place. This freezing behavior is a natural response to threat (Cantor, 2009). A mouse
is put into a test chamber and exposed to an aversive stimulus (i.e. shock) that is paired with a
neutral stimulus (i.e. white noise) and the mouse then associates the light with the shock. During
Pavlovian fear conditioning this association between an aversive stimulus and accompanying
neutral stimuli is formed via activation of various brain areas including the hippocampus and
amygdala (Kim & Jung, 2006; Maren, 2008). The associative memory processes activated during
this type of conditioning have also been observed in humans through imaging studies in PTSD
patients (Bremner, 2004; Bremner, et al., 2005).
Multiple symptoms, both behavioral and biological, found in PTSD patients are modeled
by PFC. Mice that are exposed to PFC show hippocampal volume changes that are similar to
PTSD patients. After undergoing an inescapable footshock reduced hippocampal volume is
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observed in mice (Golub et al., 2011). PTSD patients also show reduced hippocampal volume
(Bremner, et al., 1995; Bremner, Randall, et al., 1997; Gurvits, et al., 1996; Stein, et al., 1997).
Hyperarousal is another symptom observed in this preclinical model, as well as, clinical PTSD
patients (Harrington et al., 2012). Mice display hyperarousal after PFC (Golub, et al., 2009) this
hyperarousal is sensitive to extinction training. Exaggerated startle response is observed in PTSD
patients (Asmundson & Carleton, 2010). PFC results in a similar increased response and the
study of this specific response uses PFC prior to startle assays and is now known a the fear
potentiated startle assay (Smith et al., 2010). Symptomatology in PTSD is long lasting, with
some patients having unresolved symptoms decades after their initial diagnosis (Bremner, et al.,
1996; Malta, Wyka, Giosan, Jayasinghe, & Difede, 2009). The changes in behavior and brain
structures persist for longer than 4 weeks in this preclinical model (Li, Murakami, Wang, Maeda,
& Matsumoto, 2006).
The behavioral and biological similarity to posttraumatic stress disorder displayed by this
particular assay, Pavlovian Fear Conditioning, makes it especially attractive to use when
investigating specific pharmacological interventions. The ability to manipulate through
pharmacological intervention or conditioning to fear responses or extinction make the type of
data that can be generated by this assay especially diverse and informative in the context of a
specific receptor system. The range of symptoms represented, in addition to the biological
similarities of PFC to PTSD, provide a strong preclinical model that would more than likely be
able to detect candidate compounds for the treatment of PTSD.
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Rationale
Post Traumatic Stress Disorder (PTSD) is an anxiety disorder that affects over 7.7 million
adults and carries an estimated societal cost of $6.2 billion. This prevalence and therefore the
cost of PTSD is increasing. Current treatments for PTSD include psychotherapy (e.g., exposure
therapy) and pharmacotherapy (e.g., antidepressants). Although there are a wide variety of
therapies that have been used and new ones are being developed, there is still no clear treatment
approach that does not leave a large portion of patients still suffering or that have spontaneous
reoccurrences of symptoms.
Our increased knowledge about PTSD has revealed that there is dysregulation of many
neurotransmitter systems in patients diagnosed with the disorder. One of the systems that is
affected is the endogenous opioid system. In addition independent analyses of medical records
indicate that exogenous opiate administration (morphine) may have a protective affect against
PTSD. Opioid analgesics, including morphine and fentanyl, are often administered as a response
to trauma. Since opioids, both endogenous and exogenous, influence neurological processes that
we know are affected in those with PTSD it is important to study how these compounds exert
this effect. This is a novel PTSD treatment avenue that has not yet been explored.
Preclinical models of psychiatric disorders are established tools that can be used to reveal
mechanisms, etiology, treatments and many other important factors of these disorders. Pavlovian
fear conditioning is believed to model the memory processes that take place in PTSD
development and has clear parallels to many of its symptoms. The open field assay can be a
measure of both anxiety and avoidance behaviors while serving as a control to indicate if tested
compounds have sedative or stimulant effects not related to fear.
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I propose using the preclinical assays Pavlovian fear conditioning and the open field to
illuminate the effects of opioids on fear behavior that models PTSD.
Because of the clinical observations involving morphine administration and PTSD;
I hypothesize that opioid compounds with mu opiate receptor (MOR) agonist properties
will decrease fear behavior in both open field and Pavlovian fear conditioning.
Also, because of previous research involving KOR antagonists;
I hypothesize that compounds with KOR antagonist properties will decrease fear
behavior in both the open field and Pavlovian fear conditioning.
.
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Methods Experiment I
The following is the first of two experiment methods; this project is broken into two
halves with similar assays with changes to methods described chronologically. The first
experiment as described below was a two day fear conditioning procedure where data was
obtained for both cued and contextual fear conditioning. Post fear testing animals were also
placed into the open field where their locomotor activity was measured. Several KOR ligands
were tested along with vehicle controls.
Subjects
Two hundred forty eight adult male C57BL/6J mice were obtained at approximately 8
weeks of age weighing 21-25 g (The Jackson Laboratory, Bar Harbor, ME) and were allowed to
acclimate to the vivarium for approximately one week prior to commencement of testing. An
N=8 was used for each experimental group (for each drug dose and its vehicle group). The mice
were housed at a maximum of four per cage in an AAALAC-accredited animal facility with food
(7012 Teklad LM-485 Mouse/Rat Sterilizable Diet, Harlan Laboratories, Inc., Indianapolis, IN)
and water available ad libitum under a 12-h/12-h light/dark cycle (lights on at 0600 h to 1800 h)
with all testing occurring during the light phase. All procedures were carried out in accordance
with the “Guide for the Care and Use of Laboratory Animals” (Institute of Laboratory Animal
Resources, National Academy Press, 1996) and were approved by the Institutional Animal Care
and Use Committee of Virginia Commonwealth University.
Drugs
The kappa opioid receptor (KOR) antagonists norbinaltorphimine (NorBNI) and (3R)-7hydroxy-N-((1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDtic) (RTI International,
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Research Triangle Park, NC) were administered 24H prior to training or testing as specified in
results. While naloxone, morphine, buprenorphine, fentanyl HCL, U50,488, enadoline and
diazepam (obtained from the National Institute on Drug Abuse, Rockville, MD) were
administered 20min prior to testing. All drugs were dissolved in sterile 0.9% saline with the
exception of diazepam (which was dissolved in 10% w/v 2-Hydroxypropyl-β-cyclodextrin
(Sigma-Aldrich, St. Louis, MO) 90% sterile 0.9% saline). All drugs were injected
subcutaneously in a volume equivalent to 10 ml/kg body weight.
Choice of drugs and doses tested. Benzodiazepines (used clinically as adjunctive
treatments for PTSD) produce anxiolytic effects in the assays proposed here (Fraser et al., 2010;
Sanger & Joly, 1985). For example, in the mouse, diazepam (0.54 mg/kg) reduced margin time
in an open field assay (Fraser, et al., 2010). Also, in the mouse, diazepam (0.52 mg/kg) reduced
duration of freezing in response to the conditioned stimulus in the PFC assay (Sanger & Joly,
1985; Smith, et al., 2010). Therefore, I propose using diazepam (0.1, 0.3, 0.56, and 1.0 mg/kg) as
my control anxiolytic drug in these assays for experiment one.
The opioid drugs proposed below have a variety of binding affinities, with the
benzodiazepine diazepam serving as the control comparison. The doses proposed are drawn from
literature as cited and when possible from the same or similar behavioral assays in C57BL/6
mice. More specifically, morphine (0.1, 1.0, 3.0 and 10 mg/kg) and fentanyl (0.001, 0.01, and0.1
mg/kg) both have a high affinity for the MOR, where they act as agonists (Minami et al., 2009).
MOR antagonist naloxone (0.1, 1.0, and 10 mg/kg) has a high affinity for MOR, though it has
antagonist action at all subtypes of opioid receptor (Middaugh, Kelley, Cuison, & Groseclose,
1999) . Clinically, morphine and fentanyl are both used by the US armed services medical corps
in the field for pain relief of injured personnel (Burnam, Meredith, Tanielian, & Jaycox,
2009)and so are especially relevant to ongoing influence on PTSD. The compounds U504880
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(0.1, 1.0, and 10 mg/kg), enadoline (0.0001, 0.001, 0.01, and 0.1 mg/kg) (KOR agonists), and
NorBNI (1.0, 10, 30 mg/kg) (KOR antagonist) have high binding affinity at the KOR which we
have shown previously can effect stress related behaviors (Beardsley, et al., 2005; Bruchas,
Land, Lemos, & Chavkin, 2009; Wang et al., 2009). The remaining drug buprenorphine (0.3, 1,
and 3 mg/kg) has partial agonist activity at MORs and antagonist activity at KORs (LelongBoulouard et al., 2006). These drugs each represent either activation or inhibition of MORs and
KORs as well as mixed MOR activation/KOR antagonism. This selection of drugs represents
different actions that might underlay opioid influence on fear behavior.
Apparatus
Fear conditioning measurements for Experiment I were conducted using two
commercially supplied, Near Infrared Video Freeze Systems controlling a total of seven
individual test chambers (MED-VFC-NIR-M, Med Associates). Each test chamber consisted of a
clear polycarbonate top and front, white acrylic back, and stainless steel sides, with a shockable
grid floor (32 cm wide, 25 cm high, 25 cm deep; Med Associates Part Number VFC-008),
enclosed in a white, sound-attenuated box (63.5 cm wide, 35.5 cm high, 76 cm deep; NIR022MD), equipped with a speaker in the side wall. A proprietary light source (Med Associates
NIR-100) provided near-infrared light (NIR; 940 nm). Video images of the behavioral sessions
were recorded at a frame rate of 30 frames per second (640 × 480 pixels, downsampled within
the driver to 320 × 240 pixels; about 1 pixel per visible mm2) via an IEEE 1394a (Firewire 400)
progressive scan CCD video camera (VID-CAM-MONO-2A) with a visible light filter (VIDLENS-NIR-1) contained within each chamber and connected to a computer in the same room.
Parameters for scoring were set to define freezing behavior as absence of movement for 1/15th
second, and percent freezing was derived in real time from the video stream by computer
software (Video Freeze; SOF-843) running on a Windows computer.
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Locomotor measurements for Experiment I were conducted in eight commercially
obtained, automated activity monitoring devices each enclosed in sound- and light-attenuating
chambers that recorded distance travelled in cm in 10-m bins via computer-controlled circuitry
(AccuScan Instruments, Columbus OH). The interior of each device was divided into separate
20x20x30 cm arenas permitting the independent and simultaneous measurement of two mice.
Sixteen photobeam sensors per axis were spaced 2.5 cm apart along the walls of the chamber and
were used to detect movement.
Procedure
The procedure used in Experiment I was synthesized following a review of broad
methodologies published in the fear conditioning literature. A summary table of these methods is
included in Table 1. This literature review revealed 32 unique sources or labs which had
published at least two separate papers involving mouse fear conditioning. The parameters of
most interest are habituation time, unconditioned stimuli time, aversive stimuli intensity and
time, inter-trial interval used and number of trials.
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Table 1
Habituation
(Event #1)

Unconditioned
Stimulus
(Event #2)

120 s
140 s
120 s
N/A
120 s
120 s
120 s
120 s
180 s
240 s
120 s
180 s
120 s
300 s
180 s
300 s

30 s
20 s
30 s
30 s
120 s
120 s
30 s
15 s
20 s
33 s
30 s
20 s
30 s
30 s
30 s
20 s

2s
1s
2s
1s
2s
2s
2s
2s
3s
3s
2s
2s
2s
2.5 s
2s
1s

Kleppisch, 2008

180 s

30 s

2s

Lattal, 2011
Lattal, 2007
MacAulay, 2010
Maren, 2009
Minichiello, 2009
Nguyen, 2002
Oitzl, 2011
Palmiter, 2011
Pape,2003
Seidenbecher, 2011
Singewald, 2011
Tonegawa,2007
Vargas-Irwin,
unpublished data
Wemmie, 2011

148 s
120 s
300 s
180 s
120 s
120 s
180 s
120 s
120 s
120 s
120 s
240 s

30 s
30 s
30 s
10 s
30 s
30 s
20 s
5s
10 s
9s
120 s
20 s

120 s
180 s

20 s
20 s

Reference
Abel, 2006
Adams, 2002
Anagnostaras, 2011
Anderson, 2010
Barad, 2005
Cain, 2004
Caldarone, 2000
Comery, 2005
Corbo, 2002
Davies, 2004
Davis,2005
Fanselow, 2010
Gulick, 2007
Heldt, 2007
Holmes, 2008
Imaki, 2009

Aversive
Stimulus
(Event #3)

Shock
Intensity

ITI

trial
#

0.7m A
0.7 mA
0.77 mA
0.6 mA
0.7 mA
0.7 mA
0.5 mA
1.5 mA
0.75 mA
0.75 mA
0.57 mA
0.5 mA
0.57 mA
0.4 mA
0.6 mA
1.0 mA

N/A
60 s
N/a
20-180 s
120 s
120 s
120 s
120 s
60 s
60 s
120 s
180 s
120 s
210 s
60-90 s
60 s

1
3
1
4
2
5
3
2
3
3
2
3
2
5
2
3

N/A

1

2s
2s
0.25 s
1s
2s
2s
2s
2s
1s
1s
2s
2s

0.7 mA
0.5-3.0
mA
0.7 mA
0.4 mA
1.0 mA
0.5 mA
0.7 mA
0.4 mA
0.3 mA
0.2 mA
0.45 mA
0.7 mA
0.75 mA

N/A
90 s
120 s
70 s
120 s
N/A
60 s
40 s
N/A
?
120 s
120 s

1
4
5
5
2
1
6
100
1
3
5
2

2s
2s

0.7 mA
0.75 mA

60 s
120 s

3
5

The habituation used by 80% of sources was 120 s long at the beginning of the first
session. The most common unconditioned stimuli were white noise (65%) or tone (25%). Shock
was almost universally (98%) used as the aversive stimuli. Inter-trial intervals (ITI) were much
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more varied with 120 s being used 50% of the time while 60 s was being used 40% of the time. I
combined these most commonly used parameters for the use in the initial fear conditioning
procedure. This procedure consisted of Conditioning (Day 1) with Context and Cue tests (Day
2) that occurred across two, consecutive days. During Conditioning (Day 1), mice were placed in
the fear conditioning chambers and after a 2 m baseline period, three tone-shock pairings were
administered (60 s ITI), consisting of a 30 s white noise (80 dBA) co-terminating with a 2 s
scrambled footshock (0.70 mA, RMS, AC constant current) delivered through the grid floor,
followed by a 2 m rest period. Mice were then returned to their home cages. Each chamber floor
was then removed and replaced with a fresh unit and the chamber walls were cleaned with
unscented non-alcohol germicidal wipes (Sani-Cloth HB) prior to the next experimental session.
The next day during Context test (Day 2), mice were placed in the chambers and exposed to the
previous conditioning context for 5 m (without tone or shock deliveries) and then returned to
their home cage. Floors were changed and interiors were cleaned as above. New cage floors were
inserted along with white opaque plexi-glass pieces which made the floor smooth and the walls a
continuous curve. After 20 m had elapsed the mice were placed in this altered context for the
Cue test. Subjects were presented with a 2 m baseline period, three 30-s white noise (80 dBA)
noise presentations (60s ITI), followed by a 2 m rest period. Mice were then returned to their
home cage.
The locomotor procedure for part one of the experiments was conducted immediately
following the measurement of cue fear testing. Mice were removed from the fear conditioning
test chamber and moved across the room to the locomotor measurement chambers. Movement
was measured continuously and binned every 10 m for a total of 60 m then animals were placed
back into home cages. Variables recorded during this procedure were Total Distance traveled
(cm) and time spent (s) in the center and edges of the open field.
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Data Analysis
Freezing was defined in parameters to be the absence of movement for 3 frames at a
sample rate of 30 frames per second; 1/10th of a second. Percent of time spent freezing was
calculated relative to the rest of the session time and was used as the main dependent variable. It
was recorded for the first 2 mof Conditioning as well as the first 5 m of Context Exposure and
Test. More specifically, the first 2 m of initial chamber exposure freezing was calculated and
used as a baseline measure. Freezing was calculated during the first five minutes of the Context
Exposure session and is presented as a test of contextual freezing. Two-way repeated measures
ANOVA followed by a Dunnett’s Test was used to compare percent freezing during the baseline
measurement with those of the Context Exposure and Test sessions to determine if conditioning
occurred, and was used to compare the experimental groups (dosage groups) with their vehicle
controls to evaluate drug effects. An N=8 was used for each experimental group. This N was
determined to have 90% power to detect a difference of means ≥ 12.00 in percent contextual
freezing with a significance level (alpha) of 0.05 (one-tailed) calculated from results of a
preliminary study comparing 10 mg/kg norBNI with vehicle-treated mice (N=8/group) (StatMate
2.0, GraphPad Software, Inc., 2004). All comparisons were considered statistically significant
when P<0.05 and were conducted using commercial software (Prism 5.0c, GraphPad Software,
Inc., 2004).
Initially, as an independent check of equipment accuracy, two observers hand scored the
time spent freezing of a group of 8 mice on 3 consecutive days post fear conditioning. Freezing
was defined to the observers as absence of movement except for respiration. Each observer
obeserved the mice in real time and recorded time in seconds subjects spent freezing using a
stopwatch. The time was totaled and divided by the total session time of 300 s to produce a
percent freezing. The machine display was blocked so the observer was blind to the machine
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score during their recording of the session. The machine scores for these same mice were
compared to the two observers’ scores. A two-way ANOVA with repeated measures on both
factors (observer and time) was conducted with simple effects between observers compared
within each time period using a post-hoc, pair-wise Holm-Sidak test adjusted for multiple testing
assuming one family for all tests (Prism 6 for Mac OSX, Version 6.0a.152, GraphPad Software
Inc., San Diego, CA). There were no main effects for observer F(2,14)=3.370, p>0.05; or for
time F(2,14)=1.1797, p>0.05. There was also no interaction between observer and time
F(4,28)=0.5436, p>0.05. This indicates that the machine scoring of mouse freezing using the
settings described above was consistent with observational measures of freezing.
For locomotor measurements during experiment one, distance travelled (cm) was
subjected to analysis by a one-way ANOVA (4 levels of drug dose) followed by a Dunnett’s
Post-Hoc Test comparing drug doses to the vehicle control group. Separately, time (s) spent in
the center vs edge of the open field was analyzed via one-way ANOVA (4 levels of drug dose)
with a Dunnett’s Post-Hoc Test comparing drug doses to the vehicle control group. All
statistical tests were conducted using computer software (Prism 5d for Macintosh, GraphPad
Software, Inc., San Diego, CA), and all types of comparisons were considered statistically
significant if p<0.05.

Results Experiment I
Preliminary studies for environment one.
Pilot Group. The percent freezing for the pilot group (N=8) varied significantly from
baseline in both contextual, F(2, 21) =5.907, p<0.001, and cue, F(2, 21) = 28.38, p<0.0001, tests.
Group differences indicated freezing was significantly higher than baseline in context (p < 0.05)
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and cue (p< 0.001) tests. While freezing was significantly lower during extinction for both
context (p < 0.05) and cue (p< 0.001) tests (Figure 1).

Figure 1. Fear Conditioning Pilot group.
This figure illustrates successful fear conditioning and extinction. Percent freezing during
context and cue tests are significantly higher than baseline. Percent freezing after
extinction training is significantly lower in both context and cue extinction conditions.
Significance is denoted by * p<0.05, **p<0.01, and *** p<0.001.
JDtic and Control Groups. The percent freezing for the JDtic and control groups (N=8)
varied significantly among the three different conditions, in both contextual, F(2,21)= 6.222,
p<0.01, and cue, F(2,21)=9.416, p<0.0001, tests. Both initial and repeated time points are within
subject and group differences indicated that the vehicle no shock control group froze
significantly less than JDtic and vehicle only during the initial context test (p<0.0001) and not
during the continued time course tests. While there was no significant difference between vehicle
and JDtic contextual freezing at any time point (Figure 2).
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Figure 2. Contextual Fear Conditioning JDtic and Control groups.
This figure illustrates that administration of the KOR antagonist JDtic increased
contextual percent freezing more than vehicle or vehicle no shock at all time points
except for the initial test day. The vehicle no shock group had significantly lower
freezing than both JDtic and Vehicle treated groups on the initial test day. Significance is
denoted by * p<0.05, **p<0.01, and *** p<0.001.
Group differences for the cue freezing tests indicated that the vehicle no shock group
froze significantly less (p< 0.001) than JDtic-treated groups at all time points measured except at
baseline. The vehicle group froze significantly less (p< 0.05) than JDtic-treated groups on Day 7
while showing no difference to no shock at the same time point (Figure 3).
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Figure 3. Cue Fear Conditioning JDtic and Control groups.
This figure illustrates that administration of the KOR antagonist JDtic increased cue
percent freezing more than vehicle no shock at all time points. The JDtic treated group
froze significantly more than either vehicle group on day 7. The vehicle no shock group
had significantly lower freezing than both JDtic and Vehicle treated groups on all days
but day 7. Significance is denoted by * p<0.05, **p<0.01, and *** p<0.001.

NorBNI and Control Groups. The percent freezing for the NorBNI treated and control
groups (N=8) varied significantly among the three different conditions, in both contextual,
F(4,35)=17.918, p<0.0001, and cue, F(3,45)=9.416, p<0.0001, tests. Group differences indicated
that the contextual freezing of the no shock vehicle group was significantly lower (p< 0.001)
than the vehicle group only on the initial test day. While among the different NorBNI dosage
groups (1, 10 and 30 mg/kg) on the initial test day, 1 and 10 mg/kg produced significantly higher
(p<0.001) freezing than either vehicle group or 30 mg/kg norBNI. The 10 mg/kg NorBNI group
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had significantly higher freezing than all other groups on Days 7 (p<0.001) and 14 (p<0.001).
There were no significant differences between groups’ freezing on Day 21 (Figure 4).

Figure 4. Context Fear Conditioning NorBNI and Control groups.
This figure illustrates that the administration of KOR antagonist norBNI significantly
increased contextual freezing on the initial test day at 1 mg/kg and 10 mg/kg doses as
compared to vehicle. The 10 mg/kg dose of norBNI increased contextual freezing during
the 7 and 14 day time points as compared to vehicle. While the vehicle no shock treated
group showed significantly less freezing than all other groups only on the initial test day.
Significance is denoted by * p<0.05, **p<0.01, and *** p<0.001.

Group differences indicated that the cued freezing of the no shock vehicle group was
significantly lower (p< 0.001) than the vehicle group only during the Day 7 test. There were no
significant differences amongst the different groups treated with NorBNI (1, 10 and 30 mg/kg)
on the initial test day there were no significant differences. On Day 7 doses of 1 and 30 mg/kg
produced significantly lower (p<0.001) freezing than vehicle treatment. On Day 14, the 10
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mg/kg NorBNI treated group had significantly higher freezing than the other dosage groups of
NorBNI but not the vehicle treated group (p<0.001). While on Day 21, NorBNI 30mg/kg
displayed significantly higher freezing than vehicle treated groups (Figure 5).

Figure 5. Cue Fear Conditioning NorBNI and Control groups.
This figure illustrates that administration of the KOR antagonist norBNI increased cued
percent freezing more than vehicle or vehicle no shock only on day 14 (10mg/kg dose).
The vehicle no shock group had significantly lower freezing than both norBNI and
Vehicle treated groups on the day 7 only. While cue percent freezing was lower in the
norBNI 30mg/kg treated group only on day 7. Significance is denoted by * p<0.05,
**p<0.01, and *** p<0.001.
Noise disturbances and stress assays. The initial pilot work for the project took place in
the fall semester of 2009 on the 6th floor of the R. Blackwell Smith Jr. Building. This
information is significant because the kappa antagonist testing along with their control groups
were tested starting in mid January of 2010, which is the month that VCU started an extensive
renovation of the 1st, 2nd, and 5th floors of the R. Blackwell Smith Jr. Building. The vivaria for
all subjects were located on the basement level of this same building. Construction in the
42

building took place both during working hours (0800-1700h) as well as after hours (17012000h). During the renovation on several separate occasions noise levels were measured in the
lab space at as high as 85 dBA but ranging between 61–75 dBA during working hours (Scosche
SPL 1000F 135DB Max SPL Meter) during the week of January 31-February 4, 2010.
The decibel levels measured in the lab space did not take into account sound frequencies
that were below or above the human range of hearing that could also have been present during
the use of the construction equipment. Previous research examining the detrimental effects of
construction noise on breeding in mice and the difference in perception of construction noise
show that mice are especially vulnerable to behavioral changes after exposure to such noise.
Swiss Webster female mice that were exposed to 70, 80, or 90 dBA of cutting saw noise during
the 1st, 2nd, or 3rd week of gestation had significantly higher numbers of stillborn pups regardless
of the time of noise exposure (Rasmussen, Glickman, Norinsky, Quimby, & Tolwani, 2009).
Further research that examined the perception of construction noise by different lab species
including humans concluded that mice were significantly more likely to be adversely affected by
and more likely to perceived construction noise that would go unnoticed by human workers
(Norton, Kinard, & Reynolds, 2011). It is also likely that this noise could act as additional
stressful stimuli that are beyond the control of the experimenter. This construction noise
therefore introduced a confound that was likely to make data interpretation of the anxiety assays
difficult if not impossible. The initiation of this construction and its possible influence on the
anxiety assays was supported by the conflicting kappa pilot testing. This led me to the conclusion
that either, tests would be put on hold until the completion of construction or equipment would
need to be relocated to a new lab space.
Control studies from environment two.
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The decision was made that since additional lab space was available and construction on
the R. Blackwell Smith Jr. Building would continue for many months that the fear conditioning
equipment would be moved to the nearby but unconnected Hunter Holmes McGuire Hall Annex.
Once equipment was reinstalled and recalibrated new control groups were tested in environment
two so that the methods could be revalidated in the absence of construction noise confounds.
The initial test groups completed in environment two were to test both the
conditioning method’s effectiveness in the new environment and to serve as shock and no shock
controls. Two groups were treated with vehicle and underwent conditioning only for one group
the shock wasn’t administered. There were no significant differences in baseline freezing
behavior. The groups were clearly different in both the context and cue tests on Day 2.
Conditioning for the no shock group did not significantly increase conditioned freezing behavior.
The shock group had significant increases in conditioned freezing. This is indicative of
successful conditioning methods. This is supported by the data from original pilot group before
noise confounds were introduced. Once these control groups were complete before additional
testing took place there was much further thought about control procedures and additional assays
available in the new environment.
In environment two lab space there were several open field locomotor apparatuses. The
open field as previously mentioned is thought to model anxiety by utilizing rodents’ instinctive
fear of open spaces and brightly lit environments (Archer, 1973; Rasmusson & Charney, 1997).
For example, in the mouse, more time spent in open or well-lit space is thought to indicate less
anxiety (Belzung & Griebel, 2001). Additionally the open field can be used as a measurement of
the changes in locomotor activity related to the suppression or activation of locomotion. This
second function of the open field is important as some of the drugs of interest in the fear
conditioning assay have known effects on locomotor behavior. Since fear conditioning measures
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conditioned immobility or freezing, drugs which effect the animals’ ability to locomote could
confound the data measured in this assay. It was decided that this second assay would give a
second layer of anxiety data as well as serve as a control for locomotor effects, and so would be
administered after fear testing.

Control data for environment two.
Fear control group. New control groups were analyzed showing that vehicle shock and
vehicle no shock control groups percent freezing differed significantly from each other F(2,14)
=74.67, p< 0.001. Further, bonferroni post hoc tests indicated that the vehicle shock group
showed significantly higher freezing in both contextual (p<0.001) and cue (p<0.001) tests while
their baseline levels of freezing did not differ (Figure 6).

Figure 6. Fear Conditioning Control groups.
This figure shows the significantly higher level of contextual and cue percent freezing
during testing for vehicle groups that were exposed to shock when compared to vehicle
no shock treated groups. Significance is denoted by * p<0.05, **p<0.01, and ***
p<0.001.
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Kappa Agonist Groups (acute).The KOR agonist enadoline showed significant effects
on freezing behavior, F(3,26)= 75.04, p<0.001. Enadoline significantly increased percent
freezing during cue testing compared to vehicle at all doses tested (p<0.001). Further, enadoline
increased freezing in contextual testing at both 0.01 and 0.1mg/kg (p<0.001) (Figure 7).

Figure 7. Fear Conditioning Enadoline groups.
This figure shows the significant dose dependant increase in freezing to both context and
cue during FC testing after the administration of KOR agonist enadoline when compared
to vehicle. Significance is denoted by * p<0.05, **p<0.01, and *** p<0.001.

Enadoline significantly affected locomotor behavior, F(3,26)= 29.96, p<0.001. Mice
given 0.001 and 0.01mg/kg enadoline spent significantly more time in the center of the open
field (p<0.001). The highest dose of enadoline 0.1 mg/kg significantly reduced total distance
traveled in the open field (p<0.001) (Figure 8).
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Figure 8. Enadoline Open Field.
This figure shows the significant dose dependant decrease of total distance traveled after
the administration of KOR agonist enadoline, as well as the significant dose dependant
increase in time spent in the center of the open field when compared to vehicle treated
groups. Significance is denoted by * p<0.05, **p<0.01, and *** p<0.001.

The effects of an additional kappa agonist U50,488 were also analyzed in fear
conditioning and open field. When U50,488 was administered there were significant effects on
freezing behavior, F(3,28)=12.64, p<0.001. U50,488 significantly increased percent freezing
during contextual and cue testing at10 mg/kg, the highest dose tested compared to vehicle
(p<0.001). Further, U50,488 also increased freezing during contextual testing at 0.1mg/kg
(p<0.001) (Figure 9).

47

Figure 9. Fear Conditioning U50,488 groups.
This figure shows the significant increase in freezing to both context (0.1 & 10 mg/kg)
and cue (10 mg/kg) during FC testing after the administration of KOR agonist U50,488
when compared to vehicle. Significance is denoted by * p<0.05, **p<0.01, and ***
p<0.001.

The KOR agonist U50,488, significantly affected locomotor behavior, F(3,28)= 5.354,
p<0.001. All doses of U50,488 significantly decreased the time spent in the center of the open
field (p<0.001) relative to vehicle control levels. The highest dose of U50,488 10 mg/kg
significantly reduced total distance traveled in the open field (p<0.001) (Figure 10).
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Figure 10. U50,488 Open Field.
This figure illustrates the significant decrease in total distance traveled (10 mg/kg) and
the significant decrease in time spent in the center of the open field (all doses) for
U50,488 treated groups when compared to vehicle treated groups. Significance is denoted
by * p<0.05, **p<0.01, and *** p<0.001.

Kappa Opioid Receptor Antagonist (acute).The KOR antagonist NorBNI was
examined and showed significant effects on freezing behavior, F(3,28) 2.021, p<0.001. NorBNI
significantly decreased percent freezing during contextual testing compared to vehicle at 10
mg/kg (p<0.001). The KOR antagonist did not significantly affect cued percent freezing s
(Figure 11).
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Figure 11. Fear Conditioning NorBNI groups.
This figure shows the dose dependant decrease in freezing to context during FC testing
after the administration of KOR antagonist norBNI (10 mg/kg) when compared to vehicle
treated groups. Significance is denoted by * p<0.05, **p<0.01, and *** p<0.001.

The KOR antagonist affected locomotor behavior in the open field F(3,28) 1.434,
p<0.001. All doses of NorBNI tested significantly reduced time spent in the center of the open
field (p<0.001) but did not significantly affect total distance traveled (Figure12).

Figure 12. NorBNI Open Field.
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This figure illustrates the significant reduction in time spent in the center of the open field
in NorBNI treated groups when compared to vehicle. Significance is denoted by *
p<0.05, **p<0.01, and *** p<0.001.

Benzodiazepine/GABAA agonist. The benzodiazepine diazepam was tested and had a
significant effect on percent freezing, F(4,15)= 8.255, p<0.001. Contextual percent freezing
increased significantly after administration of 0.56 or 1.0 mg/kg diazepam (p<0.01 and p<0.001
respectively) compared to vehicle administration. However, cue freezing increased significantly
only at 1.0 mg/kg diazepam (p<0.001)(Figure 13).

Figure 13. Fear Conditioning Diazepam Groups.
This figure illustrates the significant increase in contextual (0.56 & 1 mg/kg) and cue (1
mg/kg) percent freezing during FC testing in diazepam treated groups when compared to
vehicle treated groups. Significance is denoted by * p<0.05, **p<0.01, and *** p<0.001.

Locomotor behavior in the open field was affected significantly by diazepam, F(4,15)=
9.074., p<0.001. The total distance traveled significantly decreased after administration of the 1.0
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mg/kg diazepam dose (p<0.001). There were no significant effects of diazepam on center time
compared to vehicle (Figure 14).

Figure 14. Diazepam Open Field.
This figure illustrates the significant reduction in total distance traveled in the diazepam
1.0 mg/kg treated group when compared to vehicle treated groups. Time spent in the
center of the open field for diazepam treated groups was not significantly different from
vehicle treated groups. Significance is denoted by * p<0.05, **p<0.01, and *** p<0.001.

Kappa Opioid Agonist Group (7 days after administration). The same enadoline
groups were tested for contextual and cue fear conditioning as well as open field locomotor 7
days after the original administration of drug and fear conditioning training. There were no
significant differences between the enadoline treated groups and vehicle treat group in percent
freezing F(3,48)=3.129, p>0.05. There were, however, still significant differences between
enadoline treated groups and vehicle treated group in the open field. Enadoline treated groups
spent significantly less time in the center of the open field, F(3,48)=20.19, p<0.001 (Figure 15)
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at all doses tested 0.001 mg/kg (p<0.001), 0.01mg/kg (p<0.05) and 0.1 mg/kg (p<0.001).
Although, there were no significant differences in total distance traveled between groups.

Figure 15. Enadoline Open Field.
This figure illustrates the significant reduction in time spent in the center of the open field
is still present 7 days after the administration of enadoline when compared to vehicle
treated groups. No significant changes in total distance traveled was present at the 7 day
test point for enadoline treated groups when compared to vehicle treated groups.
Significance is denoted by * p<0.05, **p<0.01, and *** p<0.001.

The same U50,488 groups were tested for contextual and cue fear conditioning as well as
open field locomotor 7days after the original administration of drug and fear conditioning
training. There were no significant differences between the enadoline treated groups and vehicle
treatment group in percent freezing F(3,56)=2.45, p>0.05. There were, however, still significant
differences between U50,488 treated groups and the vehicle treated group in the open field.
U50,488 treated groups spent significantly less time in the center of the open field,
F(3,56)=7.247, p<0.0001 (Figure 16) at all doses tested 0.1 mg/kg (p<0.001), 1mg/kg (p<0.001)
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and 10 mg/kg (p<0.05). Although, there were no significant differences in total distance traveled
between groups.

Figure 16. U50,488 Open Field.
This figure illustrates the significant reduction in time spent in the center of the open field
for U50,488 treated groups, when compared to vehicle treated groups, is still present 7
days after administration. No significant lasting reductions to total distance traveled were
observed at the 7 day test point. Significance is denoted by * p<0.05, **p<0.01, and ***
p<0.001.

Discussion Experiment I
Pilot and control data from environment one.
The significant differences between baseline context and extinction groups in the original
pilot animals show that the initial methods result in effective conditioning of both contextual and
cued fear in C57BL/6J mice. Further manipulation of methods was not attempted at this time and
additional control groups for testing kappa receptor compounds were completed.
The next compound investigated was the kappa receptor antagonist JDTic along with two
vehicle control groups; one control group with the aversive stimulus present (vehicle shock) and
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one with no aversive stimulus present (vehicle no shock). JDTic did not significantly reduce
contextual freezing and only significantly reduced cued freezing at the 7 day test point. These
results were disappointing given the anti-stress effects previously noted in other paradigms with
this compound. However, more troubling than the lack of JDTic’s effects was the somewhat
erratic results of the control groups which showed no differences to one another on several time
points, even though one control group did not receive any exposure to the aversive shock stimuli.
Concurrent testing of a full dose effect curve of the different kappa receptor antagonist
NorBNI with two similarly treated control groups resulted in the exacerbation of freezing
behavior and also showed similar overlap between the shock and no shock vehicle groups.
NorBNI significantly increased freezing behavior to both the conditioning context and cue at
certain time points. The most interesting result was the dramatic increase in freezing behavior in
the vehicle no shock control group to the conditioned cue on all but one time point tested.
Acute kappa modulation of fear behavior.
The kappa agonist enadoline significantly increased freezing in both cue and context
conditions when administered subcutaneously prior to testing. This increase in freezing was dose
dependant and occurred at doses where locomotor behavior was not significantly lower than
vehicle. The highest dose tested significantly reduced the total distance traveled in the open field.
While, a significant increase in the amount of time the animals spent in the center of the open
field was observed at the intermediate and highest dose. The two different assays results support
the anxiogenic profile of enadoline, and show that it specifically exacerbates conditioned
freezing in C57BL/6J mice. Acute enadoline administration produces changes in locomotor
behavior consistent with increased anxiety.
The kappa agonist U50,488 was also tested in both Pavlovian fear conditioning and the
open field. The results with U50,488 were similar to those produced by enadoline though
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slightly more erratic. There was significant exacerbation of freezing indicative of anxiogenic
affect. Conversely, locomotor behavior indicated more time was spent in the center of the open
field, which is normally interpreted to mean less anxiety. Again, both results occurred at doses
that did not suppress locomotion. The highest dose tested of U50,488 suppressed locomotion and
this marked suppression may explain the conflicting results with increased center time. The
animals are normally placed in the center of the open field at the beginning of the test session. It
is possible that their locomotion was so reduced that instead of moving to the edge of the open
field as is normally observed, the mouse could not move from the center at all. This could also be
interpreted as freezing in the fear conditioning test and so it is important to note this when trying
to interpret data from this assay when locomotion is suppressed by the test compound.
The kappa antagonist norBNI was administered immediately after training due to its
unique pharmacokinetics and testing took place as normal on day two. There was a significant
decrease in freezing behavior at the intermediate dose tested but only in contextual freezing,
cued freezing was not affected. Interestingly, total distance traveled was not affected but animals
spent significantly less time in the center of the open field. This conflicting result between the
two assays was the first sign that the current method of measurement, while serving as a control
for gross locomotor effects, may not be an accurate measure of anxiogenic effects.
The kappa data may indicate that the open field when run as a within subjects assay after
fear conditioning may be affected as much by the fear conditioning procedure as it is by the test
compounds. There are also indications that at doses where locomotion is affected that freezing
behavior and locomotor suppression may be indistinguishable in the Pavlovian fear conditioning
assay. This shows that controlling for locomotor confounds is important in interpreting this data.
This confound concern becomes more apparent when testing a benzodiazepine.
Acute benzodiazepine modulation of fear behavior.
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The benzodiazepine and GABAA agonist diazepam was tested and significantly
exacerbated freezing behavior in both contextual and cued conditions. However context fear was
affected at the intermediate dose while cue was affected only by the highest dose tested.
Additionally, locomotor behavior shifted away from the center of the open field with significant
reductions in total distance traveled at the highest dose tested. The data from both assays seem to
indicate that acutely diazepam, at the doses tested, contrary to expectations produces anxiogenic
effects.
Diazepam has long been used as an anxiolytic drug in humans (trade name Valium®) and
shows similar effects in other mammals including mice (Boissier, Simon, & Aron, 1968). Further
exploration of the literature show that the anxiolytic effects of diazepam and other
benzodiazepines are sensitive to prior experience in the testing context in other anxiety assays
like elevated plus maze and light dark box (Holmes, Iles, Mayell, & Rodgers, 2001; Rodgers &
Shepherd, 1993). Prior experience in the anxiety inducing test environment lessens the anxiolytic
effects of diazepam (Holmes, et al., 2001; Rodgers & Shepherd, 1993). This may be the effect
we are observing here as the Pavlovian fear conditioning methods depend on the previous
conditioning of the test environment paired with an aversive stimulus prior exposure is necessary
before testing.
The conflicting and unexpected data resulting from these two assays in conjunction was
of concern. Locomotor effects were important confounds to control for and yet the second assay
using the open field was not yielding results which clarified the data. Instead the open field used
as a within subject assay seemed to further complicate the data. Groups were tested under the
acute influence of drug effects which included the possible confound of locomotor suppression.
In an attempt to clarify the effects of the acute drug exposure on fear behavior without the
confounding locomotor suppression testing was conducted again in the kappa agonist groups
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when the animals were in a non-drug state one week post conditioning, in the groups that had
already undergone testing.
Lasting changes to baseline locomotor behavior.
There were no lasting significant effects to conditioned freezing behavior. The open field
still showed a significant reduction of the time spent in the center area. This implies a lasting
increase to basal levels of anxiety. The vehicle groups did not display the lasting changes and
instead showed an almost equal distribution of time spent in the center verses the edge of the
open field. However, it is impossible to conclude that this change to level of anxiety like
behavior is due completely to the administration of the kappa agonists alone. It may have been a
combination of the anxiogenic activation of the kappa system in conjunction with the
conditioning that led to this change. It also may have been the combination of the kappa
activation and the pre-exposure to the locomotor chambers. These data suggest that an
interaction occurred in one of three ways. Either, the drug effected locomotor behavior directly
obscuring freezing data interpretation. The fear conditioning training effected locomotor
behavior. Or the pre-exposure to the locomotor or conditioning context had an effect on final
testing.
The overall change in baseline behavior well after drug exposure is fascinating. The
investigation of fear conditioned animals in a non-drug state after drug exposure is important in
the context of PTSD in that the phenomenon is long lasting and subject to spontaneous
reoccurrence. In further study regarding modifying methods to remove locomotor confounds as
well as incorporate a non-drug state a publication by Cain, et al. (2004) seemed to offer better
methods choices. There was a test day comparable to my original methods, extinction exposure
training, and an additional non-drug test period (Cain, Blouin, & Barad, 2004).
Transition to new methods.
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I decided to adopt procedures that were a synthesis of both the Cain procedure and my
original methods. This synthesis of procedures allowed for a direct comparison of my previous
data (Day 2) as well as a data point free of drug locomotor influence (Day 3). An additional gain
by using these procedures was the exposure learning extinction component. While the day three
extinction measures gave a non-drug state data point, it was also after an extended exposure to
the training environment. This adds to the preclinical model a data point that could be used as a
comparison to drug administration during exposure therapy in clinical settings. While this model
uses rodents, it has been observed that the same memory processes (Siegmund & Wotjak, 2006)
that occur during extinction learning are mirrored in humans and that the extinction of
conditioned fear has served as the explicit model for behavior therapy of human anxiety
disorders (Craske, 1999; Davis, 2011; Wolpe, 1969). The process of the progressive weakening
of the conditioned response by repeated presentations of CS without the US, is the basis of
exposure therapy (Cain, et al., 2004). This added component can be used to postulate not only
the mechanism of opioids influence on fear but how use of these analgesics could impact
treatment of PTSD.
Within the new procedures approach I decided to concentrate on the contextual fear
component (though there is one measurement of cue fear effects). The brain areas involved in
contextual fear conditioning are primarily the hippocampus and the amygdala (Anagnostaras,
Gale, & Fanselow, 2001). Infusion of the NMDA receptor antagonist D,L-2-amino-5phosphonovaleric acid (APV) into the hippocampus is sufficient to block the acquisition of
contextual fear (Young, Bohenek, & Fanselow, 1994). The local infusion of APV into the
basolateral amygdala blocks the acquisition of tone or contextual fear (Campeau, Miserendino, &
Davis, 1992; Fanselow & Kim, 1994; Maren, Aharonov, Stote, & Fanselow, 1996). Lesion
studies support the necessary involvement of both these brain areas and the connections between
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them, high-frequency stimulation of the pathways carrying information from the hippocampus to
the amygdala produces LTP, and lesions of these projections selectively block the acquisition of
contextual fear (Maren, 1996; Maren & Fanselow, 1995).
Opioids have been linked to inhibition of major neurotransmitters in the hippocampus
and the amygdala (Wagner, 1996). Mu agonists have been shown to inhibit the release of
norepinephrine and acetylcholine in the hippocampus (Jackisch, Geppert, Brenner, & Illes, 1986;
Jackisch, Geppert, & Illes, 1986; Werling, Brown, & Cox, 1987). Kappa agonists have also been
shown to inhibit the release of both norepinephrine and acteylcholine (Jackisch, Geppert,
Brenner, et al., 1986; Jackisch, Geppert, & Illes, 1986; Werling, et al., 1987). Using a mossy
fiber synaptosomal preparation, very high concentrations of kappa agonist could inhibit both
dynorphin and glutamate release (Gannon & Terrian, 1991). The decision to focus on contextual
fear after the change in methods I believe is well supported by the known distribution of opioid
receptors in both the hippocampus and amygdala as well as the interconnected functions of these
two brain areas. It is further supported by the evidence of the suppression by opioids of key
neurotransmitters like glutamate and norepinephrine that are involved in the learning process
(Gannon & Terrian, 1991; Jackisch, Geppert, Brenner, et al., 1986; Jackisch, Geppert, & Illes,
1986; Werling, et al., 1987).
Another change in the new methods is the use of a measurement of level of movement
while the animals are in the conditioning chambers, the motion index. As explained in the data
analysis portion of methods the motion index is the number of pixels that have changed within a
designated time period more than they would change if the mouse was not present (i.e., video
noise). A calibration is run at the beginning of each session prior to the subject being placed in
the chamber and that video is used with that session as the comparison video. In other words
each session has its own individual reference video used as the baseline control. Since this
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motion index is being generated in chamber during the fear sessions this removes some
confounds associated with measuring locomotor behavior post session in a different
environment. One reason locomotor testing was introduced was the concern for drug induced
locomotor effects. However, I found that measurement of those effects in a new environment
some time after drug administration and conditioning made for interesting if difficult to interpret
data. The data indicate that there was an impact on locomotor activity; however, it is difficult to
know if this difference was due to the conditioning or the drug administration. Another concern
was the difference in drug time course. Initially locomotor activity was measured after both test
session had already occurred so a minimum of 51 minutes had elapsed since drug administration.
While this may not be a problem for some of the longer acting drugs it is certainly possible that
the drug would no longer be acting centrally by the time locomotor was measured. The motion
index when used as a measurement of general movement can be indicate overall levels of
activity during the conditioning and test sessions which removes the concern of drug time course
and measurement in a new environment.
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Rationale Experiment II
Change in Methodology.
Refining locomotor activity measurements. During the measurement and analysis of
part one of experiments several challenges which complicated and possibly confounded data
interpretation were recognized. The first of these challenges was the interpretation of locomotor
data. Animals were first tested in the Near Infrared Video Freeze Systems, and then placed in the
Open Field for locomotor measurements. This initiated two concerns. One was the change of
context in which the animals’ behavior was being measured. Previous reports indicate that
contextual cues specifically influence the severity of freezing behavior and that measurement in
a novel context can be used to measure the degree of generalizability of the conditioned fear
response (Gonzalez, Quinn, & Fanselow, 2003). In changing the context that locomotor
behavior is measured in, the data are less clearly interpreted with regard to the fear conditioning
tests. The second challenge is the possibility that the fear conditioning has, in itself, modified
basal levels of open field locomotor activity. Though there are no direct data in mice showing a
modification of open field activity by fear conditioning, it has been shown that activity in these
two assays share genetic framework (Sokoloff, Parker, Lim, & Palmer, 2011). The proposed
change in methods would use a movement measure that is recorded during the fear conditioning
session, which would remove this concern. Additionally, the time course in which the
components of the experiments take place (20 m, 40 m and 47 m post injection) give rise to the
concern that there are different amounts of central drug activity taking place during the fear tests
than is taking place during the locomotor tests. With these challenges in mind I shifted to using
the Motion Index analysis described below.
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Refining contextual fear measurements. A second concern was that in working with
both cue and contextual fear tests it became clear that the drugs administered were having
differential effects in the two tests. While both sets of results were interesting and continued
exploration of the cue fear response is warranted, I chose to focus on contextual fear
conditioning in a new modified procedure. These methods were based on the methods in a report
that focused not only on acute contextual fear but on drug effects during both acute contextual
freezing and a measure of extinction (Cain, et al., 2004). This additional testing condition occurs
in an absence of acute drug activity. The new methods outlined below provide a measurement of
contextual freezing and the influence of drugs administered before this test that is comparable to
the previous methods. Additionally the animals are exposed to the conditioning context that is
then measured as a level of extinction learning and how it was affected by the drug
administration. This testing occurs in a non-drug state and provides data on the effects of acute
drug administration while avoiding the complication of acute drugs effects on movement. Also,
as described above, contextual fear conditioning involves the hippocampus as well as the
amygdala. One of the ways I postulate opioids may be influencing fear behavior by their effects
on learning itself, this would most likely involve a hippocampus-dependant mechanism. Based
both on the preliminary data with the experiments in part one, as well as a desire to more closely
replicate the methods presented in (Cain et al., 2004) I chose to focus on contextual freezing of
Pavlovian fear conditioning.
I hypothesize that opioid compounds with MOR agonist properties will decrease fear
behavior in Pavlovian fear conditioning and facilitate extinction.
Also, because of previous research involving KOR antagonists;
I hypothesize that compounds with KOR antagonist properties will decrease fear
behavior in Pavlovian fear conditioning and facilitate extinction.
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Methods Experiment II
The following is the second of two experiment methods. The second experiment as
described below is a three day fear conditioning procedure where data were obtained for
contextual fear conditioning and its extinction. Animal’s activity was measured in real time in
the fear conditioning chambers. Several KOR ligands and MOR ligands were tested along with
vehicle controls.
Subjects
Four Hundred sixty four adult male C57BL/6J mice were used in Experiment II with all
other aspects of their treatment remaining the same as in Experiment I.
Drugs
The KOR antagonist norbinaltorphimine (NorBNI) (RTI International, Research Triangle Park,
NC) was administered 24H prior to training or testing as specified in results. While naloxone,
morphine, buprenorphine, fentanyl HCL, U50,488, enadoline and diazepam (obtained from the
National Institute on Drug Abuse, Rockville, MD) were administered 20min prior to testing. All
drugs were dissolved in sterile 0.9% saline with the exception of diazepam (which was dissolved
in 10% w/v 2-Hydroxypropyl-β-cyclodextrin (Sigma-Aldrich, St. Louis, MO) in 90% sterile
0.9% saline). All drugs were injected subcutaneously in a volume equivalent to 10 ml/kg body
weight.
Choice of drugs and doses tested. Drugs used in experiment two are justified in the
methods for experiment one. All is the same with the exception of the removal of JDtic and
diazepam from testing.
Apparatus
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Fear conditioning measurements for Experiment II as well as locomotor measurements
for Experiment II were conducted using two commercially supplied, Near Infrared Video Freeze
Systems as described in Experiment I.
Procedure
The procedure used in Experiment II was a modification of those described in (Cain, et
al., 2004) and consisted of a Conditioning (Day 1), Context Exposure (Day 2) and a Test (Day 3)
that occurred across three, consecutive days. During Conditioning (Day 1),mice were placed in
the fear conditioning chambers and after a 2-min baseline period, three tone-shock pairings were
administered (60s ITI), consisting of a 30-s white noise (80 dBA) co-terminating with a 2-s
scrambled footshock (0.70 mA, RMS, AC constant current) delivered through the grid floor,
followed by a 2-min rest period. Mice were then returned to their home cages. Each chamber
floor was then removed and replaced with a fresh unit and the chamber walls were cleaned with
unscented non-alcohol germicidal wipes (Sani-Cloth HB) prior to the next experimental session.
The next day during Context Exposure (Day 2), mice were placed in the chambers and exposed
to the previous conditioning context for 20 m (without tone or shock deliveries) and then
returned to their home cage. During the Test on Day 3, mice were placed in the chambers for 5
min as a measurement of the extinction of contextual freezing. Percent freezing was recorded as
the dependant variable and was analyzed as is described in the next section.
Locomotor measurements during part two of testing were simultaneously recorded along
with freezing and are presented as the Motion Index (MI). The MI represents a general activity
level of the animal and is used as a measure to control for direct motor effects of the drugs being
tested. As a control for drug effects only the MI on Day 2 was analyzed (this period directly
followed drug administration). This Index was recorded as a dependant variable and was
computed and analyzed as described in the next section.
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To ascertain the persistence of drug effects on extinction, time course testing was
conducted. This testing used the same methodology as described above with a Conditioning (Day
1), Context Exposure (Day 2) but with varied durations before the Test day. For the drug
enadoline the dose (0.1 mg/kg) which significantly facilitated extinction was tested using
separate groups of mice for each time point test day. The different time points were Day 3, Day
7, and Day 14. Drug administration occurred just as with previous methods preceding Context
Exposure on conditioning Day 2.
A time course of effects was also generated for the norBNI dose (30 mg/kg) which
significantly facilitated extinction. Due to the unique pharmacokinetics of norBNI(Endoh,
Matsuura, Tanaka, & Nagase, 1992) drug administration occurred immediately post conditioning
on day 1 and the time course was extended to include Day 21 and Day 28 test groups.
Data Analysis
Freezing was defined to be the absence of movement for 3 consecutive frames at a sample rate of
30 frames per second; 0.10 of a second. Percent of time spent freezing was calculated relative to
the rest of the session time and was used as the main dependent variable. It was recorded for the
first 2 m of Conditioning as well as the first 5 m of Context Exposure and 5 m on Day 3 Test.
More specifically, the first 2 m of initial chamber exposure freezing was calculated and used as a
baseline measure. Freezing was calculated during the first 5 m of the Context Exposure session
and are presented as a test of contextual freezing and the five minutes of test on Day 3 are
recorded and presented as a test of extinction of contextual freezing. Two-way repeated measures
ANOVA followed by a Dunnett’s Test were used to compare percent freezing during the
baseline measurement with those of the Context Exposure and Test sessions to determine if
conditioning occurred, and was also used to compare the experimental groups(dosage groups)
with their vehicle controls to evaluate drug effects. An N=8 was used for each experimental
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group. This N was determined to have 90% power to detect a difference of means ≥ 12.00in
percent contextual freezing with a significance level (alpha) of 0.05 (one-tailed) calculated from
results of a preliminary study comparing 10 mg/kg norBNI with vehicle-treated mice
(N=8/group) (StateMat 2.0, GraphPad Software, Inc., 2004). All comparisons were considered
statistically significant when p<0.05 and were conducted using commercial software (Prism 5.0c,
GraphPad Software, Inc., 2004).
For locomotor measurement during part two of experiments, were conducted via a
proprietary motion analysis algorithm that was used to generate a Motion Index from the digital
video stream in order to estimate the amount of mouse movement. This algorithm analyzed the
video stream in real time, as it was being saved to disk, and it was capable of analyzing up to
four video cameras simultaneously recording at 30 frames per second, 320 × 240 pixels, 8-bit
grayscale. Briefly, a reference video sample is taken prior to placing the mouse into the chamber
(“calibration”). This reference sample establishes the amount of baseline noise inherent in the
video signal on a per pixel basis, across multiple successive frames. Once the mouse is placed in
the chamber, successive video frames are continuously compared to each other and to the
reference sample on a pixel by pixel basis. Any differences between pixels in the current video
signal larger than those in the reference sample are interpreted as animal movement. These
differences (in pixels) are summed for each image frame, and this summation is counted as the
Motion Index. The Motion Index is the number of pixels that have changed within a designated
time period more than they would change if the mouse was not present (i.e., video noise). For
video storage, the four streams from the four chambers are saved into one Windows Media
Video 9 file (WMV3 codec), 320 × 240 pixels (32 bits) per stream, 30 frames, with a variable
total bitrate averaging about 1200 kb/s. Motion Index numbers were analyzed in a one-way
between subjects ANOVA (4 levels of drug dose) with a Dunnett’s Test post hoc analysis
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comparing drug doses to the vehicle control group. All statistical tests were conducted using
computer software (Prism 5.0c, GraphPad Software, Inc., San Diego, CA), and all types of
comparisons were considered statistically significant if p<0.05.
Results Experiment II
Experiment II drug studies.
KOR Agonists on Contextual Fear. The KOR agonist enadoline was tested and
significantly increased contextual freezing F(4,35)= 6.736, p< 0.001 on Day 2 (of the new
methodology). Post hoc analysis revealed that the two highest doses of 0.01 mg/kg and 0.1
mg/kg significantly increased freezing behavior compared to vehicle on Day 2 (Figure 17). The
highest dose of enadoline (0.1 mg/kg, p<0.01) also significantly facilitated the effects of
exposure extinction training on Day 3 F(4,35)= 6.736, p< 0.001 (Figure 17).

Figure 17. Enadoline Contextual Fear.
This figure illustrates that the percent freezing to context was significantly increased on
Day 2 after administration of the KOR agonist enadoline (0.01 & 0.1 mg/kg) when
compared to vehicle. Also, when enadoline is administered prior to extinction training
the 0.1 mg/kg dose significantly facilitated the extinction of contextual conditioned
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freezing that was measured on Day 3 verses vehicle treated groups. Significance is
denoted by * p<0.05, **p<0.01, and *** p<0.001.

There were also significant differences between enadoline treated groups and vehicle
treated groups in motion index scores on Day 2 F(4,19)=15.06, p<0.0001. The highest two doses
of enadoline (0.01 mg/kg and 0.1 mg/kg, p<0.0001) significantly reduced motion index scores
compared to vehicle on Day 2 (Figure 18).

Figure 18. Enadoline Activity Data.
This figure illustrates the significant dose dependant reduction in the activity scores that
were measured on Day 2 conditioning in enadoline verses vehicle treated groups.
Significance is denoted by * p<0.05, **p<0.01, and *** p<0.001.

The KOR agonist U50,488 was tested and did not significantly increase contextual
freezing F(3,28)= 1.254, p< 0.3092 on Day 2 (Figure 19). All doses of U50,488 (0.1 mg/kg,
p<0.05, 1.0 mg/kg p<0.01, and 10 mg/kg p<0.001) significantly facilitated the effects of
exposure extinction training on Day 3 F(3,28)= 65.37, p< 0.0001 (Figure 19).
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Figure 19. U50,488 Contextual Fear.
This figure shows that there was no significant difference in freezing to the conditioned
context in KOR agonist U50,488 treated groups when compared to vehicle treated
groups. However, in groups that received U50,488 on Day 2 during extinction training
there was a significant facilitation of the extinction of freezing to the context when
compared to vehicle treated groups. Significance is denoted by * p<0.05, **p<0.01, and
*** p<0.001.

There were also significant differences between U50,488 treated groups and vehicle
treated groups in motion index scores on Day 2 F(3,28)=4.500, p<0.05. The highest (10 mg/kg,
p<0.01) and lowest doses (0.1 mg/kg, p< 0.05) of U50,488 significantly reduced motion index
scores compared to vehicle on Day 2 (Figure 20).
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Figure 20. U50,488 Activity Data.
This figure illustrates the significant reduction in the activity scores that were measured
on Day 2 conditioning in U50,488 treated groups (0.1 mg/kg & 10 mg/kg) verses vehicle
treated groups. Significance is denoted by * p<0.05, **p<0.01, and *** p<0.001.

KOR Antagonists on Contextual Fear. The KOR antagonist nor-BNI was tested and
significantly reduced contextual freezing F(3,28)=7.054, p< 0.01 on Day 2. Dunnett’s post hoc
analysis revealed that the all three tested doses 1 mg/kg, 10 mg/kg and 30mg/kg significantly
(p<0.001) decreased freezing behavior compared to vehicle on Day 2 (Figure 21). The highest
dose of norBNI (30 mg/kg, p<0.01) also significantly facilitated the effects of exposure
extinction training on Day 3 (Figure 21).
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Figure 21. NorBNI Contextual Fear.
This figure illustrates the significant reduction in percent contextual conditioned freezing
on Day 2 in all norBNI treated groups when compared to vehicle. Also, shown is the
facilitation of extinction by the either; the administration of norBNI 30mg/kg before
extinction training, or its continued activity maintaining a significantly lower freezing
percentage than vehicle treated groups on Day 3. The interpretation of Day 3 data is
complicated by norBNI’s extended time course of effects in vivo. Significance is denoted
by * p<0.05, **p<0.01, and *** p<0.001.

There were also significant differences between norBNI treated groups and vehicle
treated groups in motion index scores on Day 2 F(3,28)= 2.664, p<0.05 (Figure22). The highest
dose 30 mg/kg, (p< 0.05) significantly raised motion index scores compared to vehicle on Day 2.
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Figure 22. NorBNI Activity Data.
This figure illustrates the significant increase in the activity scores that were measured on
Day 2 conditioning in norBNI 30 mg/kg treated verses vehicle treated groups.
Significance is denoted by * p<0.05, **p<0.01, and *** p<0.001.

Time Course of Contextual Fear Extinction. The KOR agonist enadoline was tested to
see if the facilitation of extinction persisted over time, compared to vehicle. The 0.1 mg/kg dose
of enadoline significantly facilitated extinction training F(3,36)=168.8, p<0.0001, evident by
significantly less freezing on Days 3 and 7 (p<0.001) as well as Day 14 (p<0.01) when compared
to vehicle (Figure 23).
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Figure 23. Enadoline Extinction Time Course.
This figure shows the contextual freezing percentages of six separate groups that
experienced Day 1 conditioning and Day 2 exposure with an additional test on either Day
3, Day 7 or Day 14. Three groups received enadoline 0.1 mg/kg on Day 2 and then varied
time point tests; while three other groups received vehicle on Day 2 and then varied time
point tests. Regardless of the time point at which extinction of freezing was measured the
enadoline 0.1 mg/kg treated groups showed significantly lower freezing than vehicle
treated groups. Significance is denoted by * p<0.05, **p<0.01, and *** p<0.001.

The KOR antagonist norBNI was tested to see if the facilitation of extinction was stable
over time, compared to vehicle. The 30 mg/kg dose of norBNI significantly facilitated extinction
training F(5,70)= 58.20, p<0.0001, evident by significantly less freezing on Days 3, 7, 14, 21,
and 28 (p<0.001) when compared to vehicle (Figure24).
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Figure 24. NorBNI Extinction Time Course.
This figure shows the contextual freezing percentages of ten separate groups that
experienced Day 1 conditioning and Day 2 exposure with an additional test on either Day
3, 7, 14, 21 or 28. Five groups received norBNI 30 mg/kg immediately after conditioning
on Day 1 were tested on Day 2 and then received varied time point tests; while five other
groups received vehicle immediately after conditioning on Day 1 were tested on Day 2
and then had varied time point tests. Regardless of the time point at which extinction of
freezing was measured the norBNI 30 mg/kg treated groups showed significantly lower
freezing than vehicle treated groups. Significance is denoted by * p<0.05, **p<0.01, and
*** p<0.001.

KOR Antagonist Blocking of KOR Agonist Effects. The KOR antagonist norBNI was
tested in conjunction with enadoline to determine if the behavioral effects were KOR mediated.
NorBNI pre-treatment blocked, F(4,35)=0.6191, p>0.05, enadoline’s significant acute
exacerbation of conditioned freezing on Day 2 (Figure 25). Furthermore, co-administration of
norBNI blocked, F(4,35)=0.6191, p>0.05, enadoline’s significant facilitation of extinction on
Day 3 (Figure 26).
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Figure 25. NorBNI+ Enadoline Contextual Fear.
This figure illustrates the percent conditioned freezing that was measured on Day 2 in
both groups which received enadoline plus vehicle, as well as, groups that received 10
mg/kg norBNI immediately after conditioning on Day 1 and then one of four doses of
enadoline on Day 2. The pretreatment of 10 mg/kg norBNI blocked the significant
exacerbation of contextual freezing by the administration of enadoline that was observed
in enadoline/vehicle treated groups. Significance is denoted by * p<0.05, **p<0.01, and
*** p<0.001.
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Figure 26. NorBNI+ Enadoline Contextual Fear.
This figure illustrates the percent conditioned freezing that was measured on Day 3 in
both groups which received enadoline plus vehicle, as well as, groups that received 10
mg/kg norBNI immediately after conditioning on Day 1 and then one of four doses of
enadoline on Day 2. The pretreatment of 10 mg/kg norBNI blocked the significant
facilitation of the extinction of contextual freezing by the administration of 0.1 mg/kg
enadoline that was observed in enadoline+vehicle treated groups. Significance is denoted
by * p<0.05, **p<0.01, and *** p<0.001.

The pretreatment of 10 mg/kg norBNI also blocked, F(5,42)=1.860, p>0.05, enadoline’s
significant motion index reduction on Day 2 as well as having no significant effects of its own on
the motion index of Day 3 (Figure 27).
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Figure 27. NorBNI + Enadoline Activity Data.
This figure illustrates the activity levels that were measured on Day 2 and Day 3
conditioning in norBNI+enadoline treated groups verses enadoline+vehicle treated
groups. No significant differences were observed in activity levels. Significance would be
denoted by * p<0.05, **p<0.01, and *** p<0.001.

MOR Agonist Effects on Contextual Fear. The Mu agonist fentanyl was tested and the
intermediate dose of 0.01 mg/kg significantly reduced freezing, F(3,28)=11.67, p<0.001 on Day
2 (Figure28). While on Day3 all three doses of fentanyl (0.001 and 0.01 mg/kg, p<0.001; 0.1
mg/kg, p<0.01) significantly facilitated extinction learning (Figure28). The intermediate dose of
fentanyl, 0.01 mg/kg, significantly increased, F(3,28)=38.51, p<0.0001, the motion index score
on Day 2 of conditioning compared to vehicle (Figure 29).
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Figure 28. Fentanyl contextual fear.
This figure illustrates the significant reduction in percent contextual conditioned freezing
on Day 2 in the fentanyl 0.01 mg/kg treated group when compared to vehicle. Also
shown is the significant facilitation of the extinction of contextual conditioned freezing in
all fentanyl treated groups when compared to vehicle treated groups on Day 3.
Significance is denoted by * p<0.05, **p<0.01, and *** p<0.001.

Figure 29. Fentanyl Activity Data.
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This figure illustrates the significant increase in activity levels that was measured on Day
2 of conditioning in the fentanyl 0.01 mg/kg treated group verses vehicle treated groups.
Significance is denoted by * p<0.05, **p<0.01, and *** p<0.001.

The MOR agonist morphine was tested and significantly reduced freezing on Day 2,
F(4,35)= 13.66, p<0.0001, at the highest two doses of 3 mg/kg and 10 mg/kg (Figure 30).
Morphine also significantly facilitated extinction shown on Day 3 at three doses (1 mg/kg and 3
mg/kg p<0.01; and 10 mg/kg, p<0.001) (Figure 30). Morphine also significantly increased
motion index scores over vehicle on Day 2 but only at the highest dose tested, 10 mg/kg,
p<0.001 (Figure 31).

Figure 30. Morphine Contextual Fear.
This figure illustrates the significant reduction in percent contextual conditioned freezing
on Day 2 in morphine treated groups (3 & 10 mg/kg) when compared to vehicle. Also
shown is the significant facilitation of the extinction of contextual conditioned freezing
by the administration of morphine (1, 3 & 10 mg/kg) before extinction training when
compared to vehicle treated groups on Day 3. Significance is denoted by * p<0.05,
**p<0.01, and *** p<0.001.
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Figure 31. Morphine Activity Data.
This figure shows the significant increase in activity levels that was measured on Day 2
of conditioning in the 10 mg/kg morphine treated group verses vehicle treated groups.
Significance is denoted by * p<0.05, **p<0.01, and *** p<0.001.

MOR antagonist effects on contextual fear.MOR antagonist naloxone was tested and
did not significantly affect freezing behavior, F(3,28)= 0.4814, p= 0.6979, compared to vehicle
on either Day 2 or Day 3 (Figure 32) . Naloxone also had no significant affects on motion index
scores, F(3,28)=1.441, p= 0.5207, on Day 2 compared to vehicle (Figure 33).
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Figure 32. Naloxone Contextual Fear.
This figure illustrates the no change in percent contextual conditioned freezing on Day 2
in naloxone treated groups when compared to vehicle treated groups. Also, shown is the
lack of a significant effect on the extinction of contextual conditioned fear in either
naloxone or vehicle treated groups. Significance would be denoted by * p<0.05,
**p<0.01, and *** p<0.001.

Figure 33. Naloxone Activity Data.
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This figure illustrates that there was no significant difference in activity level that was
measured on Day 2 of conditioning in naloxone treated groups verses vehicle treated
groups. Significance would be denoted by * p<0.05, **p<0.01, and *** p<0.001.

MOR Antagonist Blocking of MOR Agonist Effects.MOR antagonist naloxone (1.0
mg/kg) was co-administered with morphine to determine if the agonist’s effects could be
blocked. The co-administration of naloxone with morphine blocked, F(4,35)= 3.96, p=0.5714,
morphine’s significant acute reduction of conditioned freezing on Day 2 (Figure34).
Furthermore, co-administration of naloxone blocked, F(4,35)= 3.96, p=0.5714, morphine’s
significant facilitation of extinction on Day 3 (Figure 35). Morphine’s significant increase in
motion index level on Day 2 was also blocked F(4,35)= 0.2773, p=0.2114, by the coadministration of naloxone (Figure 36).

Figure 34. Naloxone + Morphine Acute Contextual Fear.
This figure illustrates the percent conditioned freezing that was measured on Day 2 in
groups which received morphine+vehicle, as well as, groups that received 1.0 mg/kg
naloxone and then one of four doses of morphine on Day 2. The co-administration of 1.0
mg/kg naloxone blocked the significant reduction in contextual freezing that was
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observed in morphine +vehicle treated groups. Significance is denoted by * p<0.05,
**p<0.01, and *** p<0.001.

Figure 35. Morphine+ Naloxone Extinction of Contextual Fear.
This figure illustrates the percent conditioned freezing that was measured on Day 3 in
groups which received morphine+vehicle, as well as, groups that received 1.0 mg/kg
naloxone and then one of four doses of morphine on Day 2. The co-administration of 1.0
mg/kg naloxone blocked the significant facilitation of the extinction of contextual
freezing that was observed in morphine +vehicle treated groups on Day 3. Significance is
denoted by * p<0.05, **p<0.01, and *** p<0.001.
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Figure 36. Morphine + Naloxone Activity Data.
This figure illustrates the blocked increase in activity level measured on Day 2
conditioning in morphine + naloxone 1 mg/kg treated groups verses vehicle treated
groups. Significance is denoted by * p<0.05, **p<0.01, and *** p<0.001.

Mixed MOR agonist/ KOR antagonist contextual fear. The semi-synthetic opioid
buprenorphine, which exhibits partial agonism at MOR and antagonism at KOR, was tested.
Buprenorphine significantly reduced freezing on Day 2, F(3,28)= 3.774, p<0.05, at all three
doses tested 0.3 mg/kg, 1 mg/kg, and 3 mg/kg, p<0.0001 (Figure 37). Buprenorphine did not
significantly facilitate extinction shown on Day 3 at any of the three doses, p>0.05 (Figure 37).
Buprenorphine also significantly increased motion index scores over vehicle on Day 2 F(3,28)=
8.936, p<0.0001 at all doses tested, 0.3 mg/kg & 1 mg/kg, p<0.0001 and 3 mg/kg, p<0.05
(Figure 38).
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Figure 37. Buprenorphine Contextual Fear.
This figure illustrates the significant reduction in percent contextual conditioned freezing
on Day 2 in buprenorphine treated groups (0.3, 1 & 3 mg/kg) when compared to vehicle.
Also shown is the lack of effect of buprenorphine on extinction of contextual conditioned
freezing when compared to vehicle treated groups on Day 3. Significance is denoted by *
p<0.05, **p<0.01, and *** p<0.001.

Figure 38. Buprenorphine Activity Data.
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This figure illustrates the significant increase in activity levels that was measured on Day
2 conditioning in buprenorphine treated groups verses vehicle treated groups.
Significance is denoted by * p<0.05, **p<0.01, and *** p<0.001.

A summary table of the results from both experiments and their findings can be found
below in Table 2. Results are grouped according to the type of ligand and their effects on the
acute expression of freezing behavior, extinction, and whether these effects were stable at
different times points tested in the time course for each drug.
Table 2
Type of Ligand
KOR agonist

Acute
Expression
↑ Freezing

Extinction
Effects
↑ facilitates

Time Course
Stable

KOR antagonist

↓ Freezing

↑ facilitates

Stable

KOR antagonist +agonist

Ø Freezing

Unclear *

MOR agonist

↓ Freezing

↑ facilitates

MOR antagonist

↔ Freezing

↔ No effect

MOR antagonist +agonist

Ø Freezing

Ø blocked

MOR agonist/KOR
antagonist

↓ Freezing

↔ No effect

Discussion Experiment II
KOR modulation of fear behavior and extinction.
Once the methods had been reworked with a concentration on contextual fear behavior
and had the added measurement of extinction, I wanted to retest the KOR compounds, enadoline
and U50,488. This was both for a direct comparison check on the new procedure but also
because the Cain article used an anxiogenic drug to facilitate extinction of fear conditioning. Our

87

previous results showed a significant exacerbation of freezing with both enadoline and U50,488
but the effects they would have on extinction had not yet been explored.
The KOR agonist enadoline was tested and in the new procedure significantly
exacerbated freezing in the conditioning context at the highest two doses (Fig 17) identical to the
original contextual measurements from the first methods. These two highest doses also
significantly reduced the motion index (Fig 18), mirroring the results of the original methods
when total distance traveled was the variable measured. However, the interesting results are the
Day 3 extinction tests which show that the highest dose of enadoline facilitated the extinction of
freezing in the conditioned context (Fig 17). This follows the results that Cain (2004) observed
using yohimbine an anxiogenic alpha 2 receptor antagonist. That two different receptor systems
can produce the same effects in a similar task is extremely interesting. It also seems
counterintuitive that an anxiogenic would improve extinction learning in an aversive task.
The KOR agonist U50,488 showed similar exacerbation of freezing in the conditioning
context in the original methods but again extinction effects had not yet been measured. When
tested using the new methods, U50,488 did not significantly exacerbate freezing in the
conditioning context (Fig 19). This was interesting because the highest and lowest doses tested
both significantly reduced motion index scores (Fig 20). I think that this shows that the motion
index is sensitive to changes in activity that are not related to increases in freezing. Though
U50,488 did not exacerbate freezing on Day 2, all doses tested facilitated the extinction of
freezing in the conditioning context. I think that this shows that the kappa activation does not
necessarily need to increase freezing to be effective as an aid to extinction learning.
The KOR antagonist norBNI was also tested using the new methods. As expected the
compound showed anxiolytic properties and decreased freezing to the conditioning context at all
doses tested (Fig 21). The highest dose tested also significantly increased motion index scores
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(Fig 22). Interestingly, the highest dose of norBNI significantly facilitated the extinction of
freezing to the conditioning context (Fig 21). This suggests that the fluctuation of motion scores
on Day 2 (either increased or decreased) is not predictive of the facilitation of extinction on Day
3. It is also intriguing that drugs with opposite actions at the same receptor can both produce
similar effects on extinction. For further clarification of these effects it was important to establish
if the extinctions effects we observed were stable over time.
The highest dose of enadoline was tested at different time points post extinction exposure
to see if the facilitation of extinction was stable. Groups were tested at either Day 3, 7, or 14 after
undergoing the same conditioning as before (Fig 23). The significantly facilitated extinction of
freezing to the conditioning context with enadoline 0.1 mg/kg was the same no matter which day
extinction was tested. All days the enadoline groups maintained a significantly lower percent
freezing than vehicle groups, indicating that this facilitation of extinction was a stable
phenomenon.
The highest dose of norBNI was tested at different time points post extinction exposure to
see if the facilitation of extinction was stable. Groups were tested at either Day 3, 7, 14, 21, or 28
after undergoing the same conditioning as before (Fig 24). The significantly facilitated
extinction of freezing to the conditioning context with norBNI 30 mg/kg was the same no matter
which day extinction was tested. All days the norBNI groups maintained a significantly lower
percent freezing than vehicle groups, indicating that this facilitation of extinction was also a
stable phenomenon.
Since drugs with opposite receptor activity were both facilitating extinction it was of
interest to see if the antagonist could block the agonist’s influence on this behavior. The
administration of 10 mg/kg norBNI in conjunction with a full dose curve of enadoline was tested.
This administration of the antagonist (administered 24 hours previous to enadoline due to
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norBNI’s unique pharmacology) blocked all significant exacerbation of acute freezing to the
conditioned context (Fig 25). Additionally the all significant motion index decreases by
enadoline were blocked by norBNI (Fig27). Day 3 data on extinction are harder to interpret. The
drug norBNI is active for at least three weeks days (Knoll & Carlezon, 2010), so the apparent
blocking of the facilitation of extinction by enadoline may be due to norBNI’s continued action
in vivo. The antagonist’s ability to block enadoline’s effects on fear behavior supports that this
modulation is happening centrally.
MOR modulation of fear behavior and extinction.
The MOR analgesics fentanyl and morphine were both tested to evaluate their effects on
acute fear behavior and the extinction of fear behavior. The analgesic fentanyl is an opioid
agonist and is slightly more selective for the mu type receptor than morphine though their
efficacy is similar (Volpe et al., 2011). Fentanyl significantly reduced freezing to the
conditioning context on Day 2 at the intermediate dose (Fig 28). This dose also significantly
increased the motion index on Day 2 (Fig 29). All three doses of fentanyl facilitated extinction of
freezing to the conditioning context (Fig 28).
The MOR analgesic morphine was also tested and is of greatest interest due to the
initiation of this project by clinical studies involving morphine’s apparent beneficial effects on
trauma patients. Morphine significantly reduced freezing acutely at the two highest doses tested
(Fig 30) while significantly increasing the motion index only at the highest dose tested (Fig 31).
This could translate clinically to the acute relief of symptoms. Morphine also significantly
facilitated the extinction of freezing to the conditioning context (Fig 30). Activation of the MOR
appears to have beneficial effects both on the acute expression of fear behavior and on the
facilitation of extinction.
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The administration of the opioid antagonist naloxone was predicted to not reduce acute
fear or affect the extinction learning process. When tested for its effects on freezing to the
conditioned context naloxone had produced no significant increase or decrease on freezing
behavior (Fig 32). Additionally naloxone did not significantly reduce or increase the
effectiveness of extinction on Day 3 (Fig 32). Locomotor effects of naloxone were no different
than that of vehicle. Naloxone administration didn’t produce any measureable effects on the
expression or extinction of contextual freezing behavior in this assay.
The beneficial effects of morphine on the extinction and expression of conditioned
freezing if produced by activation of mu receptors centrally should be blocked by the coadministration of naloxone. Naloxone (1 mg/kg) was administered in conjunction with a full
dose curve of morphine. Co-administration of naloxone blocked the significant reduction of
freezing to the conditioned context produced previously by morphine (Fig 4) on Day 2.
Additionally, naloxone co-administration on Day 2 blocked the facilitation of the extinction of
contextual freezing observed previously in the 1, 3, and 10 mg/kg morphine groups (Fig 35). The
significant increase in motion index scores on Day 2 produced by the highest dose of morphine
was also blocked by naloxone (Fig 36).
Mixed MOR agonist/KOR antagonist modulation of fear behavior and extinction.
The previous results suggest that the activation of MOR in conjunction with the
antagonism of KOR might have beneficial effects on conditioned contextual freezing. The drug
buprenorphine is a partial agonist at MOR and an antagonist at KOR, and is used clinically as a
replacement treatment for opioid addiction as well as for chronic and acute pain (Howland,
2010). Buprenorphine was tested to ascertain its effects on freezing to the conditioned context.
There was a significant decrease in contextual freezing on Day 2 at all doses of buprenorphine
tested (Fig 37). Motion index was significantly increased for Day 2 at all doses tested (Fig 38)
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but there was no facilitation of extinction by buprenorphine (Fig 37). The large increase in
motion index makes data interpretation difficult as the declines in freezing may be due solely to
locomotor activation effects. Regardless of Day 2 interpretation, no lasting changes were
observed in freezing behavior on Day 3.
General Discussion and Conclusions
Overall, between the two experiments, there is evidence that opioid compounds can influence the
expression and extinction of conditioned fear in C57BL/6J mice. In Experiment I it was observed
that KOR agonists acutely exacerbated conditioned freezing in cue and contextual tests. There
were some reductions in locomotor activity in the open field with kappa agonists and some long
lasting increases in anxiety like locomotor behavior. It is unclear from the results of Experiment I
if that change was solely due to KOR modulation, or was due to fear conditioning as similar
changes were seen in the KOR antagonist groups. KOR antagonist norBNI reduced conditioned
freezing acutely, and had no acute reduction in locomotor activity though as mentioned
previously, it did result in the same pro-anxiety reallocation of behavior away from the center of
the open field. These results supported previous research indicating that KOR antagonists
display anxiolytic properties (Beardsley, Pollard, Howard, & Carroll, 2010; Carey, Lyons, Shay,
Dunton, & McLaughlin, 2009; Schindler, Li, & Chavkin, 2010; Sperling, Gomes, Sypek, Carey,
& McLaughlin, 2010) and that KOR agonists display anxiogenic properties (Carey, et al., 2009;
Lemos, Roth, & Chavkin, 2011; Pezze & Feldon, 2004; Ponnusamy, Nissim, & Barad, 2005;
Schindler, et al., 2010; Sperling, et al., 2010).
The conflicting results seen in the open field data showing that both compounds
appeared to induce anxiogenic behavior could reflect a limitation of this procedure in predicting
anxiolytic effects (Prut & Belzung, 2003), or could have been confounded by the exposure of the
mice to the fear conditioning paradigm before exposure to the open field. One approach to
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addressing the possible confound would have been to test additional groups of animals in the
open field with just drug exposure instead of drug and fear learning exposure. Another method to
counteract this confound was to use the movement index calculations generated within the fear
conditioning chamber at the time of exposure as the measure of activity.
Additionally, in Experiment I diazepam, a positive allosteric modulator of GABAA
receptors, was shown to also increase conditioned freezing and at the highest dose reduced
locomotor activity in the open field. Initially, it was assumed that diazepam would serve as a
positive control in this experiment as it is used as an anxiolytic clinically. Unfortunately,
diazepam did not produce the expected anxiolytic like behavior in this assay. One explanation
for this may have been that the majority of source material on diazepam in anxiety assays is in
rats not mice (Asth, Lobao-Soares, Andre, Soares, & Gavioli, 2012; Shikanai et al., 2010;
Zbinden & Randall, 1967). The previous research in mice exploring the effects of diazepam is
mostly in other anxiety assays, elevated plus maze, light dark box, passive avoidance (Crestani,
Assandri, Tauber, Martin, & Rudolph, 2002; Crestani et al., 2002; Pamplona et al., 2011). The
effects of diazepam in other anxiety behavior assays is as predicted, but in fear conditioning the
data are less consistent or diazepam is given prior to consolidation, not post training (Crestani,
Assandri, et al., 2002; Crestani, Keist, et al., 2002; Pamplona, et al., 2011). Mice undergoing
trace fear conditioning, for example, display enhanced freezing when given diazepam (Crestani,
Keist, et al., 2002). This leads me to conclude that diazepam in this assay did not display
anxiolytic properties. This left me without a positive control in this model, but this reflects the
lack of a ‘gold standard” in clinical treatment for this disorder. The two approved treatments for
PTSD as discussed previously are SSRI’s that do not produce anxiolytic effects with acute
treatment. Therefore, it was decided to proceed with additional testing without this control, and
interpret the obtained data based solely on the differences relative to vehicle conditions.
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In Experiment II the same general results were observed for KOR agonists (increased
conditioned contextual freezing) and KOR antagonists (decreased conditioned contextual
freezing) acutely. In the newly obtained extinction data, however, it was observed that both KOR
agonists and KOR antagonists facilitated extinction to conditioned contextual freezing. When a
time course experiment was conducted, both the KOR agonist and the KOR antagonist
facilitation of extinction were stable over several weeks with freezing levels staying at near
baseline levels. When the KOR agonist (enadoline) and antagonist (norBNI) were coadministered, no increase in conditioned freezing was observed on Day 2. The KOR antagonist’s
blocking of the acute exacerbation of freezing suggests that behavioral response is KOR
mediated. However, Day 3 extinction data are difficult to interpret due to the long lasting effects
of norBNI (Endoh, et al., 1992; Knoll & Carlezon, 2010). The facilitation of extinction by
enadoline appears to be blocked by norBNI, but since norBNI is still pharmacologically active
(Knoll & Carlezon, 2010) the level of conditioned freezing on Day 3 may reflect the continued
antagonism of KOR.
Possible pathways for KOR modulation of fear conditioning.
The KOR in humans is distributed throughout the central nervous system and in
peripheral tissues (Peng, Sarkar, & Chang, 2012). The highest concentration of KOR is in the
putamen followed by the nucleus accumbens and caudate nucleus. While a moderate amount of
KORs are also found in the hippocampus, substantia nigra, and dorsal root ganglion (Peng, et al.,
2012). The endogenous ligands for KOR are the opioid peptides dynorphin A, dynorphin B,
and α/β-neo-endorphin.(Day et al., 1998; Goldstein, Tachibana, Lowney, Hunkapiller, & Hood,
1979) which activate the both subtypes of the KOR 1 & 2 (Nyberg & Hallberg, 2007). Kappa
opioid receptors are g-protein (Gi/G0) coupled receptors. When activated by either endogenous
ligands or exogenous ligands (e.g., dynorphin, enadoline, U50,488), there is a subsequent
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increase in phosphodiesterase activity. Since phosphodiesterases break down cAMP, this
produces an inhibitory effect on neurons (Konkoy & Childers, 1993; Lawrence & Bidlack, 1993;
Schoffelmeer et al., 1988). However, KORs also couple to inward-rectifier potassium and to Ntype calcium ion channels (Henry, Grandy, Lester, Davidson, & Chavkin, 1995; Tallent, Dichter,
Bell, & Reisine, 1994). Recent studies have also demonstrated that agonist-induced stimulation
of the KOR, like other G-protein coupled receptors, can result in the activation of mitogenactivated protein kinases (MAPK). These include extracellular signal-regulated kinase, p38 MAP
kinases, and c-Jun N-terminal kinases(Belcheva et al., 2005; Bohn, Belcheva, & Coscia, 2000;
Bruchas, Macey, Lowe, & Chavkin, 2006; Bruchas, Xu, & Chavkin, 2008; Bruchas, Yang, et al.,
2007; Kam, Chan, & Wong, 2004).
Stress has been shown to result in the release of many neuropeptides, among them
dynorphin (Lemos, et al., 2011). One type of stress in mice that has been linked to the increase in
release of dynorphins is forced swim stress. Mice that underwent forced swim showed activation
of both KORs and p38 MAP kinase co-expressed in GABAergic neurons in the nucleus
accumbens, cortex, and hippocampus; furthermore, this activation was KOR dependant as KOR
knockout mice or wild type mice treated with norBNI did not show this activation (Bruchas,
Land, et al., 2007). The activation of KORs, in mice, by exposure to a stressor like forced swim
or by administration of a KOR agonist, has been shown to potentiate the reinforcing effects of
drugs of abuse in behavioral assays like conditioned place preference, intracranial self
stimulation and ethanol (Carey, et al., 2009; Schindler, et al., 2010; Sperling, et al., 2010).
Administration of the KOR antagonist norBNI blocks these stress-induced increases and KOR
activation (Beardsley, et al., 2010). Genetic knockout of the KOR also blocks the stress-induced
increases in these behaviors (Carey, et al., 2009; Schindler, et al., 2010; Sperling, et al., 2010).
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These observations show a definite link between activation of the KOR and stress as well as a
demonstrating that a blockade of the KOR can attenuate this effect.
Short term stress exposure in humans and rodents has long been observed to result in an
increase in DA release in brain areas including the mesolimbic pathway and the nucleus
accumbens (NAc) (Abercrombie, Keefe, DiFrischia, & Zigmond, 1989). Intense or chronic
exposure to stress results in a decrease in DA in those same brain areas (Jensen et al., 2003;
Marinelli et al., 2007). Stress and KOR activation show similar behavioral responses in the
above mentioned assays and the activation of KOR has been shown to reduce DA in NAc (Pezze
& Feldon, 2004; Ponnusamy, et al., 2005). Systemic administration of the KOR agonist
salvonorin A reduces DA release in the NAc (Ebner, Roitman, Potter, Rachlin, & Chartoff,
2010) as does the KOR agonist U50,488 (Di Chiara & Imperato, 1988). The inhibition of
dopamine transmission reduces conditioned fear (Pezze & Feldon, 2004). The systemic
administration of both sulpiride, a dopamine2 (DA) receptor antagonist and the antipsychotic
clozapine (a DA2 antagonist as well as other actions) facilitate extinction of conditioned fear (Jay
et al., 2004; Ponnusamy, et al., 2005), while the administration of quinpirole (a DA2 agonist)
partially blocks extinction (Nader & LeDoux, 1999). This seems to indicate that a reduction of
DA within the NAc results in an increased efficiency in extinction learning whether induced by a
KOR agonist indirectly or direct DA2 antagonism. In patients with PTSD a single photon
emission computerized tomography (SPECT) imaging study revealed brain activity in the NAc
was found to be higher than in controls (Liberzon et al., 1999). The reduction in DA in this brain
region suggests that KOR agonists might be returning this brain area to a more normal level of
activity though it is unknown if mice have an increase in basal levels of NAc activity post fear
conditioning.
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Additionally, changes in the DA levels in the NAc core verses the NAc shell have been
shown to modulate memory consolidation (LaLumiere, Nawar, & McGaugh, 2005; Stevenson,
Sullivan, & Gratton, 2003), and so the changes in this brain area could be improving the memory
consolidation of extinction learning, though the acute effect is one of increased conditioned
freezing. However, KOR activation in other learning models like novel object recognition is not
effective in facilitating learning (Schindler, et al., 2010).
The mechanism by which KOR antagonists produce their long acting effects has been
investigated and one hypothesis attributes it to stimulating c-Jun N-terminal kinase (JNK)
phosphorylation (Bruchas, Yang, et al., 2007). Pretreatment of mice with the JNK inhibitor
SP600125 before norBNI attenuates the long acting antagonism. The phosphorylation of JNK
results in the functional disruption of KOR signaling (Bruchas, Yang, et al., 2007). KOR
antagonists exhibit an overall anxiolytic and antidepressive profile in many preclinical assays
(Beardsley, et al., 2005; Knoll, Meloni, Thomas, Carroll, & Carlezon, 2007). When tested in rats,
KOR antagonists norBNI and JDTic dose-dependently increase open arm exploration in the
Elevated Plus Maze without affecting Open Field behavior. They both also decreased
conditioned fear in the Fear Potentiated Startle paradigm (Knoll, et al., 2007). This may indicate
that KOR antagonists may be particularly effective for the treatment of comorbid depressive and
anxiety disorders (Knoll, et al., 2007).The long term blockade of the KOR activation pathway
results in the lack of activation of downstream KOR targets like extracellular signal-regulated
kinase, p38 MAP kinases, and c-Jun N-terminal kinases (Belcheva, et al., 2005; Bohn, et al.,
2000; Bruchas, et al., 2006; Bruchas, et al., 2008; Bruchas, Yang, et al., 2007; Kam, et al., 2004).
Administration of KOR agonists in humans is reported to be aversive and depressive (Mizrahi et
al., 2007). As mentioned above, KOR activation the NAc reduces dopamine function, which is
associated with depressive and aversive effects in rodents (Nestler & Carlezon, 2006) though we
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saw that it can also result in facilitation of extinction. It is possible that KOR antagonists make
stress less aversive by counter acting the intracellular signaling cascades that regulate dynorphin
expression (McLaughlin, Marton-Popovici, & Chavkin, 2003; Pliakas et al., 2001).
Possible pathways for MOR modulation of fear conditioning.
As previously mentioned, MOR agonist analgesics (i.e., morphine and fentanyl) are
amongst the most common clinically prescribed pain relievers. They act through MOR
activation, and MOR are located in diverse areas of both the CNS and PNS (Peng, et al., 2012).
The highest concentration of MORs are located in the cerebellum, NAc, caudate nucleus,
putamen, cortex and dorsal root ganglion (Peng, et al., 2012). Not only are these drugs used as
pain relievers, but are used and abused not only among the general population but among PTSD
patients. One study of US armed forces service members found that those with mental disorders
were 2.5 more times as likely to be prescribed opioids, twice as likely to receive two or more
concurrent prescriptions for opioids and a third more likely to seek early refills on opioid
prescriptions (Seal et al., 2012). A previous study from the same group found that 11% of
veterans of Iraq and Afghanistan conflicts met the criteria for substance abuse disorder and of
those up to 75% received a concurrent diagnosis of depression or PTSD (Seal et al., 2011).
It is no surprise that opioids might possibly be used to alleviate anxiety. Many studies
have demonstrated that during morphine withdrawal humans display anxiety and depressionrelated behaviors and there are corresponding behavioral responses in animals (Anraku, Ikegaya,
Matsuki, & Nishiyama, 2001; Rezayof, Hosseini, & Zarrindast, 2009). Anxiety and depression
associated with morphine withdrawal can be alleviated by the administration of antidepressant or
anxiolytic drugs, such as fluoxetine (Zomkowski, Santos, & Rodrigues, 2005). In a preclinical
model of anxiety, the elevated plus maze, pretreatment with morphine attenuates the restraint
stress induced reductions in open arm entries and time spent in the open arms as compared to
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vehicle treated controls (Anand, Gulati, & Ray, 2012). Rats experiencing persistent
inflammatory pain induced by intraplantar injection of complete Freund's adjuvant show an
anxiety phenotype in the elevated plus maze and the open field. This anxiety phenotype is
reversed when rats were treated with morphine (Parent et al., 2012). Heroin addicted individuals,
in comparison with healthy volunteers, exhibit significantly lower levels of adrenocorticotropic
hormone, as well as have reduced levels HPA axis activation in response to a stressor (Gerra, et
al., 2004; Ho, et al., 1977). Naloxone, an opiate receptor antagonist, increases HPA axis activity
by blocking an inhibitory opioidergic influence on hypothalamic CRF secretion, and patients
with PTSD have been reported to exhibit an exaggerated HPA axis response to naloxone.
Interestingly, naloxone also has been shown to reverse the analgesia of PTSD patients after
exposure to traumatic reminders. Also, PTSD patients exhibit increased CSF β-endorphin levels,
suggesting increased activation of the endogenous opioid system. The opiate receptor antagonist,
naltrexone, has been reported to be effective in treating symptoms of dissociation and flashbacks
in traumatized patients (Newport & Nemeroff, 2000; Strawn & Geracioti, 2008). Morphine
pretreatment attenuated stress induced release of NE in the thalamus, hypothalamus,
hippocampus, amygdala and midbrain in rats subjected to restraint stress (Tanaka, et al., 1983).
Stress is considered a contributing factor in the vulnerability to opiate abuse and can play
a role in initiating relapse in subjects with a history of abuse (Gaal & Molnar, 1990; Goeders,
1998, 2003; Hyman, Fox, Hong, Doebrick, & Sinha, 2007; Ilgen, Jain, Kim, & Trafton, 2008).
Previous research also indicates that stress can alter individual sensitivity to opiates as well as
suggesting that stress influences the synthesis and effectiveness of clinically used opiates
(Benedek & Szikszay, 1985; Christie & Chesher, 1982; Christie, Trisdikoon, & Chesher, 1982;
Sinha, 2001; Sinha, Catapano, & O'Malley, 1999; Sinha, Kimmerling, Doebrick, & Kosten,
2007; Stohr et al., 1999; Sutton, Grahn, Wiertelak, Watkins, & Maier, 1997). Conversely, long
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term use of opiates can affect HPA axis responsiveness to stress and induce a greater individual
sensitivity to stress-related psychiatric disorders (Burnett, Scott, Weaver, Medbak, & Dinan,
1999; Calogero et al., 1996; Carey, et al., 2009; Price, Risk, Haden, Lewis, & Spitznagel, 2004;
Yamauchi, Shibasaki, Wakabayashi, & Demura, 1997). These known interactions between
opioids and stress suggest that the effects we see in this model strengthens the theory that opioids
influence and are influenced by stress.
One brain area that is of specific interest in the interaction of opiates and stress is the
locus ceruleus, the major brain norepinephrine-containing nucleus. Many opioidergic peptides,
including MOR agonists and antagonists, are known to act in the locus ceruleus (Kreibich et al.,
2008; Reyes, Chavkin, & van Bockstaele, 2009; Reyes, Drolet, & Van Bockstaele, 2008; Reyes,
Glaser, Magtoto, & Van Bockstaele, 2006; Reyes, Johnson, Glaser, Commons, & Van
Bockstaele, 2007; Tjoumakaris, Rudoy, Peoples, Valentino, & Van Bockstaele, 2003; Van
Bockstaele, Branchereau, & Pickel, 1995; van Bockstaele, Colago, & Pickel, 1996). The locus
ceruleus is activated during stress exposure and opiates can influence this response (Valentino,
Foote, & Page, 1993; Valentino & Wehby, 1988a). Chronic opiate use (Aghajanian & Wang,
1987; Duman, Tallman, & Nestler, 1988; Fiorillo & Williams, 1996; Valentino & Wehby, 1989)
and chronic stress (Cuadra, Zurita, Lacerra, & Molina, 1999; Curtis, Pavcovich, Grigoriadis, &
Valentino, 1995; Curtis, Pavcovich, & Valentino, 1999), chronic CRF (Conti & Foote, 1995,
1996)have been shown to induce changes in LC plasticity.
Environmental stimuli provoke phasic reactions of locus ceruleus neurons, which is associated
with enhanced NE release in target regions (Berridge & Abercrombie, 1999; Florin-Lechner,
Druhan, Aston-Jones, & Valentino, 1996). Opiates can also change the firing of the locus
ceruleus (Bremner, et al., 1996).
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In addition to arousal, the locus ceruleus-NE system is hypothesized to facilitate shifts in
type of attention, from focused to scanning. This is supported by locus ceruleus recordings in
nonhuman primates during a focused attention task (Aston-Jones, Rajkowski, & Cohen, 1999;
Rajkowski, Kubiak, & Aston-Jones, 1994; Usher, Cohen, Servan-Schreiber, Rajkowski, &
Aston-Jones, 1999). Inattention, drowsiness and poor task performance are associated with low
tonic locus ceruleus discharge rate. Conversely, focused attention and optimal behavioral
performance are associated with higher tonic locus ceruleus discharge rates, coupled with robust
phasic responses to stimuli. If the increase tonic discharge rates are too excessive, then there is a
reduction in attention to the target stimuli and poor task performance(Aston-Jones, et al., 1999;
Rajkowski, et al., 1994; Usher, et al., 1999), which may indicate an inverted U-shaped
relationship between tonic locus ceruleus activity and focused attention. This could be important
when considering learning in response to environmental stimuli including stressful ones.
There is evidence of opioid receptor localization in the locus ceruleus and
electrophysiological data showing opiate influence on locus ceruleus activity. The three classes
of opioid receptors, MOR, DOR and KOR are prominently distributed within the LC (Van
Bockstaele, et al., 1995; Van Bockstaele, Chan, & Biswas, 1996; Van Bockstaele, Chan, &
Pickel, 1996).The MOR is localized postsynaptically within noradrenergic processes (Van
Bockstaele, Chan, & Pickel, 1996; Van Bockstaele, Colago, Moriwaki, & Uhl, 1996), while the
DORs and KORs are mainly localized on axon terminals (Kreibich, et al., 2008; Reyes, et al.,
2009; van Bockstaele, Commons, & Pickel, 1997),this may mean that KOR and DOR have a role
in the presynaptic release of neurotransmitters. Activation by endogenous or exogenous ligands
of MOR on neurons in the locus coeruleus has an inhibitory effect in this region, and this is
supported by in vivo and in vitro data (Aghajanian & Wang, 1987; Korf, Bunney, & Aghajanian,
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1974; Valentino & Wehby, 1988b; J. L. Williams, Drugan, & Maier, 1984; J. T. Williams, Egan,
& North, 1982).
The inhibitory action of MOR is linked to normal stress reactivity of the locus ceruleus
because when stress exposure ends neurons there are transiently inhibited, this effect can be
blocked by local micro-infusion of naloxone (Curtis, Bello, & Valentino, 2001). The local microinfusion of naloxone into the locus ceruleus blocks activity of MOR. This blockade results in
neuron activity in the locus ceruleus remaining elevated even though stress is over, which
suggests that release of endogenous opioids might normally serve to return the activity of the
locus ceruleus to normal levels (Curtis, et al., 2001). If put into terms of PTSD, continued high
level of activity in the locus ceruleus could be reflected in the hyperarousal symptoms of the
disorder. The release of endogenous opiates or the administration of exogenous opiates might
serve to modulate the return of the locus ceruleus-NE system to normal function after exposure
to stress has ended. When an individual is exposed to stress, CRF activates the locus ceruleus
and attention is shifted from task oriented to scanning attention (Curtis, et al., 2001). This shift in
attention can promote behavioral flexibility, but if shifted too far from baseline or for too long
(after stress has ended) this can have a detrimental effect on cognitive processing (Curtis, et al.,
2001). Data suggests that at the termination of stress endogenous opioids are released to inhibit
the locus ceruleus system and return activity back to normal (Curtis, et al., 2001; Valentino,
Page, & Curtis, 1991).
The data from my behavioral experiments show that both MOR and KOR ligands affect
mouse conditioned freezing behavior. These results support the growing evidence that opioids
are important compounds that influence stress behavior and should be further characterized due
to their possible use as treatments in stress related disorders like PTSD, as well as, to understand
stress related abuse consequences of opiates clinically.
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Implications for the treatment of PTSD.
The data obtained in these preclinical experiments can be applied to our current clinical
approach to PTSD treatment. The systemic administration of KOR agonists enadoline and
U50,488 acutely exacerbated freezing behavior. However, if the KOR agonist administration
took place shortly before an exposure extinction training session, then the extinction of freezing
to the conditioned context was more effective than in animals treated with vehicle. If we apply
this result to exposure therapy that is used with PTSD patients it suggests that there is a
possibility that administration of a KOR agonist during exposure therapy could make this
therapy more efficient as well as more effective. Exposure therapy is one of the most effective
behavioral therapies in use with PTSD patients (Cooper, et al., 2005; Hetrick, et al., 2010).
However, it is only successful in approximately 40% of patients. A second major concern which
might contribute to this lack of efficacy is high dropout rates (~30%) during the lengthy
treatment (8-15 weeks) (Cooper, et al., 2005; Hetrick, et al., 2010). It would then follow that if
effective a KOR agonist might reduce the treatment length needed which may result in a higher
therapy completion rate. An added benefit that might also be suggested by the data is that the
administration of a KOR agonist might also make the therapy more effective regardless of effects
on treatment length. The KOR antagonist norBNI produced reductions in acute conditioned
freezing behavior as well as hastening extinction learning. So if applied to patients with PTSD
that would mean that norBNI might provide acute symptom relief as well as improve the efficacy
of exposure therapy. This would be a double benefit as current pharmacotherapies aren’t
effective immediately. These data provide, further support for this protective relationship when
we consider the current observations regarding MOR analgesics and their link to the reduced
chances of developing PTSD. My data show that the administration of MOR agonists, morphine
and fentanyl, shortly before measurement of acute conditioned freezing results in the significant
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reduction in this behavior. This indicates that if applied to PTSD treatment the administration of
MOR agonists might result in an acute reduction of some PTSD symptoms. This may help
explain the increased rates of substance abuse in PTSD patients (for self-medication) and
supports the use of MOR agonist analgesics in PTSD at risk populations. Additionally, the
administration of MOR analgesics before exposure extinction training also produced more
efficient extinction learning. The administration of MOR analgesics could function similarly as
KOR agonists if used in conjunction with exposure therapy, but would also have the added
benefit of acute symptom relief. The use of these MOR agonist analgesics, at or near the time of
trauma, should have the added benefit of reducing later PTSD risk, and so it would be of interest
to see if this holds true for non-injured PTSD at risk populations.
Finally, my results show that buprenorphine, a mixed MOR agonist/ KOR antagonist,
might have a use as an adjunctive therapy in PTSD. While there seem to be no long term
reductions in conditioned freezing, much like MOR analgesics or KOR antagonists, fast acute
relief of some symptoms might be obtained using buprenorphine as an adjunctive treatment with
SSRIs.
More study with opioid compounds is necessary before an understanding of their full
impact on anxiety and posttraumatic stress disorder can be understood. So far however, it seems
that the administration of opioids have generally beneficial effects on conditioned fear behavior.
Most of the compounds investigated here are already used or at least have been studied in
humans. The growing prevalence and lack of a “gold standard” treatment for posttraumatic stress
disorder underline the importance of continuing to investigate the impact of opioids on this
disorder and its treatment.
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